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The aim of this study was to investigate the influence of soft tissue 
decomposition on the stability of drugs incorporated in hair antemortem. 
Two burial trials were conducted: in the first trial, rats were administered 
oxycodone over five days; in the second trial, rats were administered 
heroin over nine days then drug abstinent for another nine days.  After 
each respective treatment the rats were sacrificed and buried in controlled 
burial microcosms. Concentrations of oxycodone and selected 
metabolites or the metabolites of heroin; 6-monoacetylmorphine and 
morphine, incorporated within rat hair and liver were measured before and 
during the decomposition process. Oxycodone was analysed in hair and 
liver samples, while morphine and 6-monoacetylmorphine were analysed 
in hair samples by ultra-performance liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS). Oxycodone concentrations in both hair and 
liver decreased as the interment period and decomposition of the 
carcasses progressed. 6-Monoacetylmorphine was not detected in any 
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1.0  Forensic Taphonomy 
Taphonomy is the study of processes and variables which involve the 
decomposition, dispersal, erosion, burial and re-exposure of organisms after 
death (Ururahy-Rodrigues, Rafael, Wanderley, Marques, & Pujol-Luzv, 2008). 
Forensic taphonomy is a subfield that examines the postmortem fate of remains 
and how taphonomic forces have altered evidence that may be the subject of 
medico-legal investigations. Forensic taphonomy incorporates aspects of 
decomposition chemistry, which is a branch of chemistry that investigates the 
chemical degradation processes that occur in soft tissue as decomposition 
proceeds. The decomposition of an organism after death is a complex chemical 
process that also alters the microenvironment immediately surrounding the 
organism.   Such alterations in the burial environment and changes to the 
organism have the potential to be used by forensic investigators in locating 
clandestine graves or in establishing the circumstances surrounding death.  
 
1.1  Forensic Toxicology  
Forensic toxicology is an interdisciplinary field, which applies toxicology, 
pharmacology and other disciplines including analytical chemistry to aid in 
medico-legal investigations. In instances where the presence or absence of 
alcohol, drugs or poisons is important to a forensic investigation, a toxicological 
examination is usually conducted, i.e. to aid in the investigation of impaired 
driving, sexual assault, fire death, homicide, or other crimes involving drugs.  
Postmortem forensic toxicology focuses on determining if drugs or poisons may 
have contributed to the cause or manner of death of an individual, which may not 
be readily diagnosed at autopsy. Deaths may be attributed to direct drug 
intoxication or indirectly due to drugs where an individual under the 
pharmacological effects of drugs has a greater chance of committing or falling 
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victim to foul play (Levine, 2003). Both forensic toxicology and taphonomy can 
serve to determine these unknowns in an interdisciplinary approach.  
 
1.2  Biological Specimens of Interest 
The body can provide a wealth of information regarding the manner and cause of 
death in many instances.  Collecting and analysing bodily fluids and tissues from 
a body for the presence or absence of drugs can be a valuable investigative aid.  
Traditional matrices of analyses are blood and urine, however if the 
decomposition of the body has progressed to a point where such samples are no 
longer available or have been contaminated by decomposition by-products, there 
are alternative specimens that can be of interest to the forensic toxicologist such 
as liver and hair.  An important issue in forensic toxicology analyses is the 
potential for changes in drug concentrations to occur, which may be induced by 
decomposition from surrounding soft tissue and the burial microclimate 
1.2.1  Liver  
The liver is the largest organ within the human body aside from skin and 
muscular tissue (Williams, James, & Franklin, 2000). This highly perfused organ, 
which lies below the diaphragm in the thoracic cavity, is responsible for 
carbohydrate storage and metabolism, metabolism of hormones, synthesis of 
blood proteins, urea formation, bile formation, as well as lipid and protein 
metabolism. The liver is also responsible for the metabolism, bioactivation and 
detoxification of endogenous and exogenous analytes. Liver cells, known as 
hepatocytes, secrete an alkaline substance known as bile that aids in digestion 
by emulsifying lipids (Williams et al., 2000).  
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The liver is divided into two lobes; the right lobe is composed of the anterior and 
posterior segments and is found in the upper right abdomen; the smaller left lobe 
is divided into the medial and lateral segments and partially overlays the 
stomach. The liver receives approximately 30% of the cardiac output and is 
approximately five percent of the total body weight (Williams et al., 2000).  
Drugs and chemicals absorbed from the gastrointestinal tract flow to the liver, 
where xenobiotic metabolizing enzymes are present in high concentrations; and 
regardless of how an analyte is absorbed into the bloodstream, it is subject to 
extraction and metabolism by the liver (Williams et al., 2000).  
The enzymes within the liver are capable of a large variety of reactions, meant to 
help in the detoxification and elimination of many xenobiotic compounds. 
Cytochrome-P450 (CYP) enzymes are one class of drug-metabolizing related 
hemoproteins. They can be found in high concentrations in the endoplasmic 
reticulum of liver cells and at lower concentrations in the lungs, kidney, intestinal 
mucosa, and brain (Williams et al., 2000). CYP enzymes catalyze oxidation 
reactions and reduction reactions, while hydrolysis reactions are catalysed by 
esterases and amidases. Such reactions are commonly referred to as phase I 
reactions. Phase I reactions generally introduce a polar group to the parent drug 
to increase its water solubility, thus aiding in drug elimination. 
Phase II reactions typically involve the conjugation or addition of a specific 
chemical compound to the parent drug and involve covalent bonding. This may 
include glucuronidation, sulfation, and glutathione conjugation to form a highly 
water soluble conjugate. An example of a phase II reaction is the glucuronidation 
of compounds, which involves the transfer of glucuronic acid from a uridine 
diphosphate glucuronic acid cofactor to a carboxyl, hydroxyl, or amine group of 
the analyte, which is mediated by a group of isozymes, uridine diphosphate-
glucuronosyltransferases (Williams et al., 2000).  
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As the liver is a main site of drug metabolism, parent drugs and metabolites may 
be present in the liver at higher concentrations than in blood. Toxicological 
analyses on a body exposed to fire and/or severe trauma, or a body found to be 
in an advanced degree of decomposition, can be difficult to achieve due to the 
absence of blood and/or urine. In cases such as this, liver may be the most 
appropriate tissue sample available at autopsy.  
1.2.2  Hair  
Mammalian hair consists of three layers; the outermost layer is known as the 
cuticle, the middle layer is known as the cortex, and the innermost layer is the 
medulla (De Cássia Comis Wagner, Kiyohara, Silveira, & Joekes, 2007). The 
cuticle surrounding the individual hair shaft consists of 6 to 10 layers of cuticle 
cells and is approximately 1 µm thick. The cuticle is colourless and protects the 
cortex. The cortex makes up the bulk of the hair and provides colour and texture 
to the hair. Keratinous protein found in cortical cells is the major component of 
hair and is insoluble and relatively resistant to proteolytic enzymes (Dawber, 
1996).  
The hair root is located below the surface of the skin and is enclosed within a hair 
follicle, which produces an epidermal outgrowth called hair. Located at the base 
of the hair follicle is the vascularized dermal papilla, which supplies nutrients to 
the growing hair. Drugs present in the blood stream can be taken up by the 
papilla. The membranes of the matrix cells in the growing hair follicle are 
localized around the papilla and are exposed to the circulating blood, lymph, and 
extracellular fluids (Dawber, 1996; Pötsch, Skopp, & Moeller, 1997). Weakly 
acidic or basic drugs that are present in the surrounding fluids of the papilla can 
diffuse across cellular membranes in its free non-ionized forms. Factors such as 
the concentration gradient across membranes, the pH of the microenvironment of 
the blood and sweat around the hair shaft, and the partition coefficient of the drug 
will influence how much drug becomes incorporated into the hair shaft. Drugs 
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with greater partition coefficients will diffuse into cells at a faster rate and 
accumulate in larger concentrations (Pötsch et al.,1997).  
Hair growth occurs in cycles of growth and dormancy referred to as the anagen, 
catagen, and telogen stages. During the anagen stage, the follicle develops and 
hair is produced over a span of four to eight years at a rate of approximately 0.22 
to 0.52 mm per day (Kintz, 2004). The rate of hair growth is important when 
chronicling drug use history through hair analysis as drugs can become 
incorporated into a growing hair shaft. An accurate case history should be used 
to confirm results of any drug testing in hair. After the anagen stage, the hair will 
enter the catagen stage, a regression period where cell division stops and the 
follicle begins to degenerate. During the latter telogen stage, the hair shaft stops 
growing completely. In humans, each hair follicle has its own cycle, independent 
of its neighbouring hair follicles. After the telogen stage another growth cycle 
commences. Approximately 85% of the hair on the scalp of an adult is in the 
anagen phase and the remaining 15% is in catagen or telogen (Kintz, 2004; 
Kronstrand & Scott, 2007).  
In a growing hair shaft, matrix cells at the base of the hair follicle synthesize 
proteins, which determine the durability and strength of the hair shaft. The 
majority of the protein synthesized in hair is keratin. Matrix cells may also acquire 
pigment as they differentiate to form hair, which determines the colour of the hair 
shaft. Melanocytes, the cells responsible for hair colour, are located at the base 
of the hair follicle and produce melanin, a coloured pigment, which is 
incorporated into keratinocytes of the hair shaft as it is formed. The colour of hair; 
black, brown, red or blonde; is a result of the type and proportions of melanin 
produced by melanocytes. White hair is due to the absence of melanin-producing 
melanocytes. Grey hair is a mixture of coloured hair with white hair and is the 
result of either dormant melanocytes, which no longer produce melanin or the 
inability of keratinocytes to incorporate melanin into the growing hair (Rothe, 
Pragst, Thor, & Hunger, 1997).  
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Although the exact mechanism in which chemicals are bound into hair is not 
known, drugs may be incorporated into hair by active or passive diffusion from 
the bloodstream to the dermal papilla, trapping drugs during keratinisation of 
newly formed cells; diffusion from sweat and sebaceous glands whose secretions 
bathe the hair shaft; or through external contamination by drugs present in the 
atmosphere from vapours or powders (Henderson, 1993; Rothe et al., 1997; 
Tsatsakis, Psillakis, & Paritsis 2000; Kronstrand & Scott, 2007).  
Keratin and melanin contain polar groups, which may be utilised as binding sites 
for drugs and metals. Lipids in hair may also serve as binding sites for drugs; 
however the exact binding sites in hair have not been determined. Amino acids, 
including aspartic acid, glutamic acid, arginine, lysine, and histidine, contained in 
keratin provide free carboxyl, amide, phenolic hydroxyl, aliphatic hydroxyl, and 
sulfhydryl groups as potential binding sites for drugs (Breuer, 1981; Pötsch et al., 
1997). 
Because hair can function as a minor excretory organ and is free from enzymatic 
metabolism, levels of drug found in hair may be proportional to drug ingestion. 
The dose-concentration relationship in hair has been examined and the results 
have been mixed. Cone (1990) examined the drug levels in beard hair in two 
subjects after morphine or codeine administration and found that the 
concentrations appeared to be dose-related. However a larger study that 
examined hair collected from subjects participating in a controlled heroin-
maintenance program by Kintz, Bundeli, Brenneisen, and Ludes (1998) 
demonstrated that using quantitative drug measurements in hair to determine the 
amount of drug ingested was not applicable due to the large degree of observed 
sample variability. Other studies have suggested using hair to monitor for 
determination of drug use, tolerance, and abstinence, as well as the 
establishment of the type of drug use, rather than trying to correlate the amount 
of drug ingested to drug concentrations found in hair (Valente, Cassini, 
Pigliapochi, & Vansetti, 1981; Tagliaro, De Battisti, Smith, & Marigo, 1998; Darke, 
Hall, Kaye, Ross, & Duflour, 2002; Kugelberg et al., 2007). 
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Drug testing in hair allows for a cumulative and retrospective reflection of long-
term drug use or abuse. Hair analysis in postmortem toxicology has several 
advantages over other methodologies employing body fluids, including ease of 
sample collection, sample stability and availability, as well as an increased 
window of detection; ranging from weeks to months, compared to hours in blood 
or days for urine (Kintz, 2004). This window of detection varies between matrices 
due to the body’s ability to metabolize and eliminate itself of drugs in blood, urine, 
saliva or sweat. Drugs incorporated into hair and nails are unique from other 
matrices including teeth and bone in that there are no metabolic or excretion 
mechanisms present to remove drugs once deposited (Guillot, de Mazancourt, 
Durigon, & Alvarex,  2007; Kronstrand & Scott, 2007). Drugs may be deposited in 
bone or teeth for a longer period of time than in blood and urine, however drugs 
may be eliminated from these samples by ion exchange or dissolution of bone 
during normal bone resorption (Jenkins, 2006).  
Hair analysis should be used in conjunction with other matrices for toxicology 
testing in forensic investigations, including blood and urine (Tebbett, 1999; 
Kronstrand & Scott, 2007). However bodies that have been subjected to 
decompositional changes or scavenging may only have hair and bone available 
for forensic examination. Alternatively, any remaining blood and tissues may be 
contaminated by postmortem redistribution, decompositional by-products or 
scavenging (Watterson, 2006).  
 
1.3  Postmortem Changes Associated with 
Biological Specimens of Interest 
1.3.1 Decomposition of Soft Tissue  
The decomposition process of a carcass or cadaver begins immediately after 
death as cells within the organism begin the process of self-digestion or 
autolysis. For carcasses buried in soil, the microbial biomass of the soil can 
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contribute to the biodegradation of soft tissue (Tibbett, Carter, Haslam, Major, & 
Haslam, 2004). The enteric flora and enzymes naturally present in the intestines 
and respiratory tract invade body tissues to breakdown soft tissue and alter 
protein, carbohydrate and fat constituents (Gill-King, 1997; Dent, Forbes, & 
Stuart, 2004).  
The onset of autolysis is rapid in cells with high levels of hydrolytic enzymes, 
including the gastric and intestinal mucosa, while it is slower in heart and liver. 
The hydrolysis and transformation of lipids, proteins and carbohydrates can 
elevate blood pH, resulting in the formation of amines, including phenethylamine, 
tyramine, and tryptamine. The process of autolysis is visualized by skin slippage 
and blistering. Microorganisms from the intestine migrate into local tissues, 
through the lymphatic system and blood spreading throughout the entire body. 
The production of gases and liquids, such as hydrogen sulphide, carbon dioxide, 
methane, and ammonia, through the catabolism of tissues by enteric and soil 
microorganisms, results in bloating or inflation of body cavities and internal 
organs. It is the bloating or inflation of the body in its entirety that marks the 
putrefaction stage of decomposition. Gas and fluid accumulation within internal 
organs are capable of rupturing with sufficient force to cause postmortem 
injuries. The by-products of putrefaction include the release of volatile fatty acids 
(Janaway, Percival, & Wilson, 1997; Vass, 2001; Vass et  al., 2002).  
Active decay is the next stage of decomposition, which is marked by the 
breakdown of muscle tissue composed of proteins and amino acids. Amino acids 
readily form additional volatile fatty acids while adipose tissue decomposes to 
form phenolic compounds and glycerols (Forbes, Stuart, Dadour, & Dent, 2004). 
In warm and moist environments, adipocere, a solid material composed of fatty 
acids, can develop from adipose tissue. Evidence of adipocere formation can 
range from weeks to months (Vass, 2001; Vass et  al., 2002).  
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The late stage of the decomposition process is advanced decay, which is marked 
by a release of decomposition fluids into the surrounding environment. Such 
fluids are composed of the liquefaction and disintegration products of soft tissue, 
which are highly concentrated sources of carbon and nutrients. With advanced 
decay, an intense localized pulse of nutrients is released from the body into the 
soil. This can result in the formation of a “cadaver decomposition island”, which is 
marked by blackened earth beneath the body (Carter, Yellowlees, & Tibbett, 2007). 
The last stage of decomposition is the dry remains or skeletonisation stage. The 
remaining hair and skin become dehydrated or desiccated, resulting in 
mummification of the body. Complete skeletonisation of a human body buried at 
shallow depths can range from approximately 6 months to over a year 
(Rodriguez, 1997; Wilson et al., 2007a). Factors that can influence the rate of 
decomposition include the pH of soil and moisture. Remains subjected to wet or 
extreme pH burial environments can degrade at a quicker rate than if subjected 
to dry, neutral-pH environments. The moisture provided by the soil, air, and body 
itself can promote the growth of bacteria and fungi (Rodriguez, 1997; Wilson et 
al., 2007a).  
Changes in pH of the soil and the body affect the decomposition process. 
Degradation of biological molecules lower intracellular pH as a result of organic 
acids produced through the breakdown of lipids and proteins. As oxygen 
availability decreases, carbohydrates ferment to form a variety of acids. 
Anaerobic bacteria in the soil and intestinal bowels also contribute to a decrease 
in pH through fermentation. Buried bodies can create an acidic environment in 
surrounding soils early in the decomposition process that later becomes alkaline 
as proteolysis occurs, which may take weeks or months (Gill-King, 1997).  
1.3.2  Decomposition of Hair   
Hair is synthesized in the hair follicle and is composed primarily of proteins (65 - 
95%), lipids (1 - 9%), pigments including melanin (0.1 - 5%) and small amounts 
of trace elements, polysaccharides and water (Clarke & Rogers, 1970; Steinert & 
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Rogers, 1973; Harkey, 1993; Dawber, 1996; Kronstrand & Scott, 2007). The hair 
shaft does not undergo biogenic change post-keratinisation and is a robust non-
skeletal tissue in decomposed bodies of forensic interest (Wilson, Dodson, 
Janaway, Pollard, & Tobin, 2007). 
There are a few published studies regarding microscopic changes that occur 
within the hair and hair root still embedded in the decomposing scalp or body 
(Petraco, Fraas, Callery, & De Forest, 1988; Tafaro, 2000; Linch & Prahlow, 
2001; Wilson et al., 2007). Two types of microscopic observations of the hair root 
include postmortem banding and brush-like proximal hair ends, also known as 
putrid roots (Petraco et al., 1988; Tafaro, 2000; Linch & Prahlow, 2001). When 
hairs originate from a body in a state of decomposition, a dark band may appear 
near the root of the hair to form a putrid root, which has a tapered or brush-like 
appearance of the proximal end (the portion of the hair closest to the root). 
Postmortem root banding typically occurs in the proximal area of the hair shaft 
where the sebaceous gland duct enters the follicle. Sebaceous gland secretions 
are the product of lysosomal enzymes, which may play a role in the formation of 
bands postmortem. Decompositional changes of hair are due in part to the burial 
microclimate, microbial actions and autolytic changes within the body (Petraco et 
al., 1988; Linch & Prahlow, 2001). 
Linch and Prahlow (2001) suggested that the decomposition process of hair roots 
mimic the natural apoptosis process at the hair root stem, with the exception that 
the telogen club is not formed during decomposition. The root of hair undergoing 
telogen may thus be resistant to banding as the keratin, which is part of the 
telogen club, is resistant to decompositional changes in the surrounding tissues 
(Hordinsky, Sawaya, & Scher, 1999). Thus root banding is not observed in all 




1.4  Fate of Drugs in Postmortem Remains 
1.4.1 Postmortem Redistribution of Drugs in Soft Tissue 
Drug degradation and drug formation, through the breakdown of drug conjugates 
formed during antemortem drug metabolism, have been observed during the 
postmortem interval (Stevens, 1984; Hearn, Keran , Wei, & Hime, 1991; Skopp, 
2004). Because of the changing pH and degradation of cellular compartments, 
the effect of postmortem redistribution (PMR) and drug stability may affect the 
detection and quantification of drugs within the decomposing body.  
PMR is the process by which the movement of fluids and degradation of cellular 
components of the body result in the migration of drugs to produce a change in 
drug concentrations after death. PMR can include the redistribution of drugs into 
blood from solid organs, including the lungs, liver, and myocardium (Yarema & 
Becker, 2005). 
The death of a cell results in a variety of fates; including the cessation of aerobic 
respiration and adenosine-triphosphate (ATP) production; an increase in 
anaerobic metabolism; and the release of the cellular contents, including any 
drug present in the cell. Lactic acid, inorganic phosphates and sodium 
accumulate within the cell to decrease intracellular pH. With cellular edema, 
organelles are destroyed with enzymatic leakage into the cytoplasm, leading to 
the leakage of cellular contents into the extracellular space. The extracellular 
molecules then enter the remnants of the cell (Yarema & Becker, 2005). 
Factors that affect PMR can be attributed to the characteristics of the drug itself 
or to the changes that are occurring within the body after death. The volume of 
distribution (Vd) of a drug, which refers to the apparent volume of bodily fluid into 
which a drug dose is dissolved, is small for drugs that are highly bound to plasma 
proteins and not to tissue components; as a result the Vd for such drugs is 
approximately equal to the plasma volume. Drugs that distribute into muscle and 
adipose tissue have a higher Vd than drugs confined to the bloodstream. Using a 
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rat model, Hilberg, Ripel, Slørdal, Bjørneboe, and Mørland (1999) demonstrated 
that drugs with a Vd greater than 3 L/kg is a good predictor that a drug will 
undergo PMR. The concentration for such drugs are greater in postmortem blood 
samples when compared to samples collected antemortem. 
Lipophilic drugs and organic bases can concentrate in solid organs, including the 
liver, lungs, and myocardium. After death, passive diffusion occurs from these 
sites to the rest of the body due to a concentration gradient. The pH of a dead 
cell also decreases to create an acidic environment, thus a basic drug will 
become ionized. As a result of cell lysis, basic drugs will distribute more readily 
throughout the body as they are transported in the acidic fluid in which they are 
dissolved (Hilberg, Bugge, Mørland, & Bjørneboe, 1992).  
Koren and Klein (1992) demonstrated using a rat model that there is a 
substantial redistribution of morphine (Vd: 2 to 5 L/kg) in blood sampled from the 
cardiac chamber (heart blood) of Wistar rats treated with 4 mg/kg of morphine 
(i.m.) within the first 24 - 96 hours after death. No substantial increases in 
morphine concentrations were observed after 96 hours. Because the 
concentration of morphine was determined by radioimmunoassay, the authors 
reported that endogenous substances may have skewed the reported levels of 
morphine as the cross-reactivity of decompositional products to morphine was 
not examined. However in a more recent study by Gerostamoulos and Drummer 
(2000), the authors demonstrated that there was no significant evidence of PMR 
for morphine and its metabolites in human autopsy subjects when antemortem 
morphine levels were compared to autopsy samples in which the postmortem 
interval ranged from 11 to 122 hours (mean: 59 hours). 
Another consideration in the analysis of drugs in soft tissue is that as most 
organs are not homogeneous and PMR can lead to different drug concentrations 
within an organ, thus it may be difficult to determine the average concentration of 
a drug within any one organ without analysing the entire organ (Gerostamoulos & 
Drummer, 2000).  
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1.4.2  Postmortem Stability of Drugs in Hair 
Although hair samples from archaeological burials appear inert, they are subject 
to biodegradation and weathering (Wilson et al., 2001). Much of the destruction, 
including fungal tunnelling, destruction of keratin and the breakdown of external 
lipids, are due to microbial activity. In contrast to the readily degradable 
keratinaceous structures of hair, Wilson et al. (2007) reported that melanin 
pigment granules are broadly resistant to microbial degradation.  
In ideal storage conditions, ambient temperature and dry atmosphere, it is 
possible to detect drugs in hair many years after death (Kintz, 2004). The scalps 
of eight Chilean and Peruvian mummies dating from 2000 BC to 1500 AD tested 
positive for benzoylecgonine, the primary breakdown product of cocaine 
(Cartmell, Aufderhide, & Weems, 1991). The stability of incorporated drugs in 
hair has been investigated under different conditions including: after cosmetic 
treatment, such as bleaching and perming (Pötsch, Skopp, & Becker, 1995; 
Jurado, Kintz, Menéndez, & Repetto, 1997); in various environmental conditions, 
such as exposure in water and soil (Pötsch et al., 1995) as well as sunlight 
(Skopp, Pötsch, & Mauden, 2000).  
Pötsch et al. (1995) subjected autopsy hair samples to a variety of treatments 
including bleaching, and partial exposure to water or soil for 6 months. Formerly 
positive drug hair samples tested negative for opioids upon exposure to water or 
soil for periods of six months. Pötsch and Skopp (1996) also demonstrated in 
controlled studies that drug concentrations in hair samples, incubated and 
saturated with known solutions of morphine, codeine and dihydrocodeine, 
decreased to 2 - 18% of their initial concentrations after bleaching and to 20 - 
30% after perming.  
Thus while the above listed studies have examined the effects of decomposition 
on the morphological structure of hair; the rate of drug incorporation into a 
growing hair shaft; the stability of drugs in collected hair samples of known 
addicts; and the stability of drugs in hair samples collected from mummified 
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bodies, there is a knowledge gap regarding the effects of soft tissue 
decomposition on the stability of drugs incorporated in hair.  
 
1.5   Drugs of Interest: Opioids  
There are many different drugs that may be encountered in a forensic 
toxicological context. One common class of drugs which has been a subject of 
abuse are prescription and illicit opioids. Opiates is a term used to describe drugs 
that are derived from the opium poppy (Papaver somniferum), while the term 
opioid refers to drugs which have morphine-like pharmacological properties 
(Kalant, 1998). As morphine is derived from the opium poppy it is considered to 
be an opiate. The sap of the poppy capsules is dried to make powdered opium, 
which contains a mixture of alkaloids of two main types: benzylisoquinoline and 
phenanthrene. Phenanthrene alkaloids include morphine, codeine, and thebaine 
(Kalant, 1998).  
1.5.1  Heroin and Morphine  
Morphine is a potent analgesic commonly used for the treatment of severe pain. 
It is regarded as the prototypical opioid and is the standard by which all other 
opioids are characterized. The primary actions of morphine are mediated by 
binding to the µ-opioid receptor. Activation of the µ-opioid receptor is associated 
with analgesia, sedation, euphoria, physical dependence, and respiratory 
depression (Kalant, 1998). Morphine exerts its principal pharmacological effects 
on the central nervous system and gastrointestinal tract.  
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Morphine is metabolized by conjugation with glucuronic acid to morphine-3-
glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G) (Figure 1). M-3-G in 
humans is an inactive metabolite and M-6-G shows an analgesic activity greater 
than the parent compound (Stuart-Harris, Joel, McDonal, Currow, & Slevin, 
2000). Minor metabolites of morphine metabolism include morphine-3-sulphate 

















































Morphine-3-glucuronide (M-3-G) Morphine-6-glucuronide (M-6-G) 
Figure 1: Structures of heroin (diacetylmorphine) and selected metabolites.  
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Modifications to the morphine structure can result in semi-synthetic opiate 
derivatives. The most important parts on the morphine molecule are the phenolic 
hydroxyl at position 3, the alcoholic hydroxyl at position 6, and at the nitrogen 
atom (Figure 1). Diacetylmorphine, also known as diamorphine or heroin, is 
made from morphine by esterification with acetic anhydride of the hydroxyl 
groups at the 3- and 6- positions to produce a diacetyl ester (Girod & Staub, 
2001; Phillips & Allen, 2006).  
Heroin has a half-life of approximately 2 to 6 minutes and is rapidly deacetylated 
by blood esterases to 6-monoacetylmorphine (6-MAM). 6-MAM is hydrolyzed by 
liver enzymes to form morphine and further conjugated to its glucuronide 
metabolites (Baselt, 2008). Illicit heroin may contain acetylcodeine, which is 
metabolized to codeine and codeine glucuronide; hence morphine, its 
glucuronides, and codeine are the main metabolites found in urine after heroin 
administration (Phillips & Allen, 2006). Heroin metabolism to morphine and 
metabolites may be complete within a few hours (Baselt, 2008). Deacetylation of 
6-MAM to morphine can be inhibited in blood samples with the addition of one 
percent sodium fluoride (Dolinak, 2005).  
To differentiate heroin use from morphine use, the presence of 6-MAM should be 
identified (Figure 2). This metabolite may be detected in blood, saliva, sweat, and 
hair after consumption of heroin. Because of the short half-life (6 to 25 minutes 
(Phillips & Allen, 2006)) of 6-MAM in blood, it may not be found. Heroin itself is 
rarely found in conventional biological matrices such as urine, blood, or saliva, 
but may be detected in hair (Pichini, Altierii, Pellegrini, Zuccaro, & Pacifici, 1999).  
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Figure 2: Metabolic pathway of codeine, heroin, and morphine. 
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The presence of 6-MAM and morphine in hair can be used to access the drug 
history of a subject. The issue of tolerance and the short half life of heroin can 
lead to difficulties in determining the manner and cause of death even if 
morphine and 6-MAM are detected in postmortem samples. Hair analysis can be 
used to determine if the descendent was drug-abstinent for a prolonged period of 
time, an active addict, or a naïve user.  
1.5.2  Oxycodone  
Oxycodone is a semi-synthetic opioid that is structurally related to codeine and 
morphine, and is derived from thebaine. Oxycodone is an opioid receptor 
agonist, which acts upon the kappa receptor and to a lesser degree, the mu and 
delta receptors (Ordóñez Gallego, González Barón, & Espinosa Arranz, 2007; 
Chan, Edwards, Wyse, & Smith, 2008). Its pharmacological effects are similar to 
other opioid analgesics; pain relief, sedation, nausea, vomiting and respiratory 
depression (Chan et al., 2008). Oxycodone has an oral bioequivalence to 
morphine in a ratio of 1:2 (Curtis et al., 1999; Ordóñez Gallego et al., 2007).  
Oxycodone is a low molecular weight (316 g/mol) opioid with greater lipophilicity 
and oral bioavailability than morphine (Ordóñez Gallego et al., 2007). With 
chronic opiate exposure, an excitatory effect emerges which can contribute to 
analgesic tolerance and opioid-induced hyperalgesia (Wang, Friedman, 
Olmstead, & Burns, 2005). Oxycodone is metabolized to form noroxycodone by 
N-demethylation and oxymorphone by 3-O-demethylation (Lalovic et al., 2006; 
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Figure 3: Metabolic pathway and structures of oxycodone and selected metabolites.  
Adapted from Baldacci et al. (2004) 
 
Oxycodone is the active ingredient in OxyContin®, from Purdue Pharma, which 
contains a mechanism to release the drug slowly over a 12 hour period. 
OxyContin® was originally developed to provide analgesia in a similar manner to 
normal-release oxycodone but with improved compliance as it is administered 
once daily, compared to two to three times daily. The controlled release 
oxycodone (CRO) formulation requires each individual tablet to have a greater 
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quantity of oxycodone as the dosing regimen is reduced to once daily. However 
chewing or crushing the tablets is a method of bypassing the extended release 
mechanism, creating one larger dose of oxycodone that can increase the 
addiction and/or overdose potential (Cone et al., 2003; Davis et al., 2003; 
Tschakovsky, 2008). CRO is available in doses ranging from 10 to 80 mg. A 160-
mg dose was withdrawn from the market in 2001. The former formulations are 
comparable to multiple doses of 5-mg tablets of immediate release oxycodone, 
Roxicodone® and Percocet®, a combined formulation of acetaminophen and 
oxycodone (Cicero, Inciardi, & Muñoz, 2005).  
 
1.6   Analytical Instrumentation  
High performance liquid chromatography (HPLC) and ultra performance liquid 
chromatography (UPLC) are analytical techniques used to identify and 
characterise compounds. Liquid chromatography (LC) separates mixtures of 
substances using packed columns, containing microspheres coated with the 
stationary phase, and the liquid mobile phase is pumped through the column with 
a high-pressure pump. In reverse-phase liquid chromatography, a polar liquid 
flows through a column packed with a nonpolar stationary phase and substances 
are separated based upon their differential interactions with the stationary and 
mobile phases.  
Capillary electrophoresis (CE) is a separation technique, which combines 
aspects of gel electrophoresis and HPLC. Separation of analytes in CE is 
dependent upon differential migration in an electrical field, however unlike gel 
electrophoresis, separation is performed in free solution and not in cast gel. 
Similar to HPLC, as separation progresses, the resolved zones produce an 
electronic signal as they migrate past a detector, eliminating the need for 
staining.  
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Both CE and LC can be coupled to a variety of detectors, including 
spectrophotometric detectors, i.e. diode-array which can identify and quantify 
analytes based upon their characteristic UV spectra, as well as electrochemical 
detectors which identify and quantify analytes based upon their redox potential. 
However the utility of such detectors are limited by their sensitivity and specificity.  
Mass spectrometry (MS) is an analytical tool capable of determining the chemical 
structure of molecules. The principle behind MS consists of ionizing chemical 
compounds to generate charged molecules or molecular fragments and 
measuring their mass-to-charge ratios (m/z). This can be accomplished by a 
variety of methods, including impacting the compound after it enters a vacuum 
with a beam of electrons, resulting in the formation of charged particles. The m/z 
is calculated from the motion of the ions as they travel through electromagnetic 
fields. An MS instrument consists of three modules: an ion source, which ionizes 
the compounds; a mass analyzer, which sorts the ions by their masses; and a 
detector, which measures the abundance and variety of each ion present.  
Traditionally MS has been coupled to gas chromatograph to form gas 
chromatograph-mass spectrometers (GC-MS). After a sample has been 
vaporized and separation has been achieved through a gas chromatograph, the 
separated compounds in their gaseous form enter into the ion source, a metallic 
filament to which voltage is applied in an ionisation technique known as electron 
impact (EI). The filament emits electrons to ionize the compounds, which may 
fragment into a predictable pattern. Intact and fragment ions pass through to the 
mass analyzer to the detector.  
Electrospray ionization-mass spectrometry (ESI-MS) is a technique used to 
produce intact ions from large analytes in solution (Fenn, Mann, Meng, Wong, & 
Whitehouse, 1989). The development of ESI-MS has resulted in the ability to pair 
MS detectors with liquid-phase chromatographic techniques, including LC and 
CE. A solution containing the analyte to be studied is dissolved in a volatile 
solvent. The analyte exists as an ion in solution and after it has been separated 
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by either LC or CE, it can undergo ionization and fragmentation within the MS to 
determine its identity and abundance.  
When utilizing ESI-MS, liquid is nebulized to form highly charged droplets, which 
are desolvated as they pass through the atmospheric-pressure region of the 
source towards a counter electrode with a flow of pure nitrogen in the counter-
current direction being continually passed through the spraying region. The 
evaporating droplets quickly decrease in size until ions of the appropriate analyte 
are produced and are directed by an electrical field from the needle towards the 
source sampling cone and through two differentially pumped regions into the 
source of the mass spectrometer (Pichini et al., 1999). The specificity and 
sensitivity of LC-MS makes it well suited for the analysis of hair as one pitfall of 
using hair as a matrix to determine the levels of drugs in the human body are the 
low concentrations incorporated into hair (ng/mg) (Srogi, 2006).  
Screening of heroin or oxycodone in hair and tissue extracts may be done by -
immunoassay, however to quantify and identify drugs in hair, chromatographic 
techniques such as CE-MS and/or LC-MS are preferred due to the separation 
ability, detection sensitivity, and specificity of the instrumental system. 
Quantification by GC-MS is also possible; however this often requires sample 
hydrolysis and derivatization prior to the extraction of conjugated metabolites, as 
not all analytes are thermally stable and separate on the GC column.  
The interface chosen for method development is ESI as the metabolites of heroin 
and oxycodone are relatively polar, of high molecular weight, and may be 
thermally labile. Each standard should be introduced into the LC-MS individually 
to determine retention times, ions to monitor, and if the analytes are suitable for 
analyses for the specific instrumental setup. Ideally at least two unique ions for 
each analyte should be chosen to monitor for definitive identification of each 
analyte (Commission of the European Communities, 2002). It is preferable to 
monitor for such ions in the selected-ion-mode or multiple-reaction-mode, rather 
than in the scan mode when there may be large background noise.  
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Selected-ion mode (SIM) or selected-reaction mode (SRM) is used when a small 
number of ions specific to the compounds of interest need to be monitored. 
Multiple-reaction mode (MRM) can be utilised with a tandem MS or MS/MS and 
involves fragmenting the sample inside the instrument and analyzing the 
products generated.  
ESI is a soft ionization technique, which means the resulting mass spectrum of a 
sample may consist of a single ion ([M+H]+, the molecular species ion in positive 
ion mode). If the retention times for the individual analytes are very similar, the 
mobile phase composition and flow rates may require adjustment.  
 
1.7  Objectives 
Concentrations of heroin metabolites and oxycodone in rat hair and liver were 
examined to determine if the decomposition process of the carcass would 
influence their stability.  A microenvironment or burial microcosm was developed 
to investigate the decomposition process of rats.  As the buried rats carcasses 
progressed through various stages of decomposition, the carcasses were 
sequentially harvested and the concentrations of oxycodone and heroin 
metabolites were determined in hair and liver. Validated extraction methods were 
applied to isolate the drugs in hair and liver, including solid-phase and liquid-
liquid extraction techniques. The concentrations of heroin metabolites and 
oxycodone in the samples were determined by UPLC-MS/MS. These 
concentrations were compared to determine if the decomposition of the 









2.0   Introduction 
Animal subjects were obtained and prepared by the University of Guelph, 
Department of Psychology Laboratory of Dr. Francesco Leri (Guelph, ON). Rat 
cadavers treated chronically with heroin or oxycodone prior to sacrifice were 
buried in controlled laboratory soil environments. The carcasses were then 
sequentially harvested to determine the effects of soft tissue decomposition on 
the stability of oxycodone and its metabolites, and heroin metabolites 
incorporated in hair. The levels of oxycodone and its metabolites, and heroin 
metabolites extracted from hair samples before and during the decomposition 
process were determined. Soft tissue, including liver and heart muscle, was also 
collected throughout the decomposition process and examined. 
 
2.1  Animal Experiments 
Sprague-Dawley rats (350 - 540 grams, Charles River, QC) were implanted with 
intravenous silastic catheters (Dow Corning, Midland, MI) in the right jugular vein 
and administered intravenous oxycodone for a period of five days of 
100/infusions/day of 1 mg/kg/infusion before sacrifice by decapitation in the first 
trial. Negative controls consisted of drug-free hair collected from Sprague-Dawley 
rats. Rats utilised in the second trial were administered heroin over a period of 
nine days at a dosage of 0.5 mg/kg/infusion; each rat received an average of 30 
infusions per day (15 mg/kg of heroin per day). Rats were sacrificed nine days 
after the last day of heroin administration by cervical dislocation. Negative 
controls consisted of a separate group of six rats that were not administered any 
drugs. 
All rats were stored at -20°C until the start of the decomposition trials. Twenty-
four hours prior to the commencement of trials, the rats were stored at 4°C. The 
carcasses were then brought to room temperature for a period of three hours 
prior to burial.  
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2.2   Chemicals and Reagents 
Methanolic solutions of 1.0 mg/mL or 100 µg/mL oxycodone, noroxycodone 
hydrochloride, oxymorphone, oxycodone-D6, noroxycodone-D3, and 
oxymorphone-D3, morphine, and morphine-D3 were obtained from Cerilliant 
(Austin, TX). Morphine-3-β-D-glucuronide (1.0 mg/mL solution in methanol with 
0.05% NaOH), morphine-6-β-D-glucuronide-D3 (100 µg/mL in methanol: water 
(1:1)), 6-monoacetylmorphine (1.0 mg/mL in acetonitrile), and 6-
monoacetylmorphine-D3 (1.0 mg/mL in acetonitrile) were also sourced from 
Cerilliant. All reagents were stored at -18ºC, and used after dilution to the 
required concentrations.  
All solvents were HPLC grade; methanol, dichloromethane, hexane, isopropanol 
(all from Fisher Scientific, Pittsburgh, PA), acetonitrile (JT Baker, Phillipsburg, 
NJ), ethyl acetate, diethyl ether, and chloroform (Caledon Laboratories, 
Georgetown, ON). All other reagents were reagent grade unless otherwise 
specified. Ammonium acetate and formic acid were obtained from Sigma-Aldrich 
(St. Louis, MO); ammonium hydroxide, potassium phosphate monobasic, sodium 
chloride, sodium hydroxide, hydrochloric acid and sulphuric acid were ACS grade 
and were purchased from Fisher Scientific (Pittsburgh, PA).  
 
2.3  Blank Specimens 
Calibrator and quality control (QC) samples were prepared using hair and liver 
obtained from rats without administered oxycodone or heroin. Collected hair 
roots were submerged for 30 seconds in approximately 2mL of dichloromethane 
with agitation to remove any external contaminants. The decontaminated 
samples were finely cut (approximately 0.5 to 1.0 mm length plucked from the 
back of the drug free rats) with a sterile razor blade. Processed samples were 
then allowed to air-dry overnight before transferring weighed samples to 
disposable borosilicate culture tubes (Fisher Scientific, Pittsburgh, PA).  
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Liver samples were collected in 60 mL polypropylene screw top containers and 
stored at -20ºC until analysis. The mass of each liver sample was measured 
upon collection.  
 
2.4  Burial Microcosms  
2.4.1 Trial 1: Oxycodone 
Thirty burial taphonomic microcosms consisting of approximately 8-9 kg of loam 
topsoil were set up in the laboratory. Each microcosm consisted of a twenty-litre 
capacity high-density polyethylene container with a gasket-fitted lid. The 
containers were filled to a depth of 10 cm with non-sterile sieved loam soil 
collected from the Decomposition Facility at UOIT and maintained at a total 
equivalent water level of 50 to 60%, and an initial pH level of 6.8 as determined 
with the Kelway Soil Acidity and Moisture Tester (Model HB-2, Kel Instruments 
Co., Inc, Wyckoff, NJ). The non-sterile loamy soil was loose, granular, 
alfisol/luvisol with a loam texture and a colour of 2.5Y 3/2 (The Globe Soil Color 
Book, 2nd Ed, 2005).  
Oxycodone-administered Sprague-Dawley rats were placed in individual 
microcosms with additional soil placed on top of each rat to create a shallow 
grave to a depth of approximately 5 cm. Oxycodone-free rats were not available 
for this portion of the study to act as a negative control.  Instead control 
microcosms contained drug-free rat hair contained within mosquito netting to 
allow the microbial organisms within the soil to directly interact with the hair.  
The headspace of each microcosm was maintained at 50% of the entire volume 
and replenished every 24 to 48 hours by removing the lid for five minute-periods 
to ensure adequate gas exchange for optimal microbial activity.  
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2.4.2 Trial 2: Heroin 
Twenty-two burial taphonomic microcosms as set up in Trial 1 were utilised with 
an observed initial soil pH level of 6.2. Heroin administered Sprague-Dawley rats 
were placed in individual microcosms with additional soil placed on top of the rat 
to create a shallow grave of approximately 5 cm deep. Six control microcosms 
contained one rat each, which did not receive the heroin treatment.  
The headspace of each microcosm was maintained at 50% of the entire volume 
and replenished every 48 hours by removing the lid for five minute-periods to 
ensure adequate gas exchange for microbial activity.  
 
2.5   Sequential Harvest 
For Trial 1 oxycodone-treated rats (n=3) in the burial microcosm were 
sequentially harvested at days 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30. For Trial 2, 
heroin treated rats (n=3) in the burial microcosm were sequentially harvested at 
days 7, 14, 28, 42, and 54, and a control rat was also exhumed with each 
harvest. For each trial, the burial surface was photographed prior to exhumation 
of carcasses to note the presence of any fungal growth. The carcass was also 
photographed in situ and visual observations were made with regards to the 
degree of inflation, marbling and/or expulsion of bodily fluids through any orifices 
of the carcasses.  
 
2.6  Sample Collection 
Approximately 20 mg of hair roots were collected, decontaminated in a 
dichloromethane rinse solution, dried at room temperature, and finely cut from 
each subject and stored in a sealed borosilicate culture tube at room temperature 
until analysis. Hair samples were collected prior to burial and again upon 
 30 
exhumation. The liver from each subject was also collected and mass recorded 
upon exhumation and stored at -20°C until analysis. In trial 2, the heart was also 
collected with the intent of comparing the different concentrations of heroin 
metabolites in different organs (liver compared to heart), however it was later 
recognized that its use was limited based upon the dosing regimen.  Instead the 
pH of the heart and liver were examined to determine if there were site 
dependent changes related to the decomposition process. 
The hair in a small area of the back of each rat was trimmed to 3-5 mm 
postmortem and approximately 20 mg of hair and root were collected at Day Ø. 
The drug content of the hair samples from each subject was then compared 
between its initial concentrations at Day Ø and the concentration at Harvest.  
Soil pH and moisture levels were measured with a Kelway Soil Acidity and 
Moisture Tester (Model HB-2, Kel Instruments Co., Inc, Wyckoff, NJ), which was 
extended 8 cm into the soil base. Measurements were taken on Day Ø and the 
day of harvest for each individual microcosm. Soil was also collected from 
beneath the carcasses, the decomposition island, and stored at -20°C until 
further analysis.  
 
2.7  Instrumentation  
2.7.1 Capillary Electrophoresis-Mass Spectrometry  
  (CE-MS) 
CE-MS analysis for oxycodone and its metabolites was performed on an Agilent 
1200 LC/MSD instrument (Agilent, Mississauga, ON) equipped with an 
electrospray ionization interface run in the positive mode (4.0 kV). An Agilent CE 
equipped with a 50 μm i.d. fused-silica capillary (Part no. G1600-67311, Agilent 
Technologies, DE, Germany) of 125cm length was connected to the electrospray 
ionization interface of the MS. Sheath gas consisted of purified nitrogen (99.5%), 
supplied by a Mistral Nitrogen Generator (Neuheim, Switzerland). The sheath 
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liquid consisted of a mixture of water: methanol (50:50 v/v) with 1% formic acid to 
support the formation of positively charged ions. The sheath liquid was infused 
into the interface at a flow rate of 4.0 μL /min. The sample was electrokinetically 
injected by applying a positive voltage for 10 kV for 20 s. 
An adapted method from Tagliaro, Manetto, Crivellente, Scarcella, & Marigo 
(1998) was used to separate and identify oxycodone, oxymorphone, and 
noroxycodone. The background electrolyte (BGE) of 25 mM ammonium acetate, 
pH 9 adjusted with 6M NH4OH was prepared daily. Prior to analysis, the capillary 
was conditioned by flushing with 0.1N NaOH, distilled water, then the BGE for  
5 minute intervals. The applied voltage during separation was 27 kV. Full scan 
mass spectra were collected in the mass range m/z 100 to 700 amu. 
Fragmentation voltage was adjusted between 65 to 120 V with a gain of 3 to 
determine unique major ions m/z for each analyte.  
2.7.2 Ultra Performance Liquid Chromatography-Tandem 
Mass Spectrometry (UPLC-MS/MS) 
The UPLC-MS/MS analysis was performed on a Waters Acquity UPLC system 
consisting of a Waters Acquity Sample Organizer Model UPC, Binary Solvent 
Manager, Micromass Quattro Ultima MS/MS TM API QAA 890 (Micromass 
Manchester, UK) instrument equipped with an electrospray interface (Turbo Ion 
Spray) with a Zorbax Eclipse XDB-C18 (150 mm x 4.6 mm, 5 µm; Agilent 
Technologies, Mississauga ON) with no guard column.  
2.7.2.1 Trial 1: Oxycodone 
The organic solvent was run through line A while the aqueous solvent was run 
through line B. Mobile phase A consisted of acetonitrile with 0.1% formic acid 
and mobile phase B was MilliQ water with 0.1% formic acid. The system was run 
in a linear gradient with an initial mobile phase composition of 10% mobile phase 
A (see Table 1 for gradient program). The total flow rate was maintained at 0.9 
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mL/min for a total run time of 10 minutes, the flow to the MS/MS was split 1:10 
with a post-column flow splitter.  
 
Table 1: Gradient elution program for oxycodone and selected metabolites on the 
UPLC-MS/MS 
Time (minutes) % Mobile Phase A  
Acetonitrile  with 
0.1% formic acid   
% Mobile Phase B  
MilliQ water with 
0.1% formic acid  
0.00 – 1.00 10 90 
1.00 – 2.00 20 80 
2.00 – 8.00 70 30 
8.00 – 9.00 100 0 
9.00 – 10.00 10 90 
 
For detection and identification, multiple reaction monitoring measurements were 
made in positive ion mode at 250˚C desolvation temperature, 100˚C source 
temperature, 50 L/hr cone gas flow, 500 L/hr drying gas flow and collision cell 
pressure at 2.0e3 bar Argon. The capillary voltage was maintained at 3.5 kV and 
the cone voltage at 35 V. The collision energy varied between 19 to 29 eV. The 
dwell time for all channels was set to 0.1s. The MS/MS parameters were 
optimized by infusing each analyte in methanol with 0.1% formic acid at a rate of 
10 µL/min, via a Hamilton 500 µL gastight #1750 syringe pump. The most 
abundant ion transition was utilised for each analyte.  
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Table 2: MRM transition ions to identify oxycodone and selected metabolites and 
respective internal standards 
Substance  Transition Mode Ion (amu) Internal Standard  
Oxycodone  316.00→241.11  Oxycodone-D6  
Oxymorphone 302.05→227.10 Oxycodone-D6 
Noroxycodone  302.05→227.10 Oxycodone-D6 
Oxycodone-D6  322.11→247.20   
Oxymorphone-D3*  305.00→231.10  
Noroxycodone-D3* 305.00→231.10  
*Oxymorphone-D3 and noroxycodone-D3 were initially part of the internal standard solution; 
however inconsistent recovery later resulted in their exclusion from the study. 
 
2.7.2.2 Trial 2: Heroin 
Mobile phase A consisted of methanol with 0.1% formic acid and mobile phase B 
was MilliQ water with 0.1% formic acid. The flow rate and gradient program was 
optimized to minimize co-elution of morphine-3-glucuronide and morphine-6-
glucuronide, which have identical molecular masses and fragmentation patterns. 
The system used a linear gradient program (Table 3) and the flow was 
maintained at 0.7 mL/min and split 1:10 to the MS. 
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Table 3: Gradient elution program for heroin metabolites on the UPLC-MS/MS 
 
 
For detection and identification, multiple-reaction-monitoring (MRM) mode was 
used in positive ion mode. The measurements were made at 350˚C desolvation 
temperature, 150̊ C source temperature, 50 L/hr cone gas flow, 500 L/hr drying 
gas flow and collision cell pressure at 2.0e3 bar Argon. The capillary voltage was 
maintained at 3.5 kV and the cone voltage at 35 V. The collision energy varied 
between 25 to 58 eV. The dwell time for all channels was set to 0.1 s.  
The MS/MS parameters were optimized by direct infusion of standard solutions 
of each analyte into the MS via a Hamilton 500 µL gastight #1750 syringe pump. 
The MRM of the molecular ions of each analyte and the two most predominant 
fragments were utilised (Table 3). The most abundant ion will be used as the 
quantifying ion, which is the ion transition that will be used to calculate the 
calibration curve and determine the concentration of morphine and 6-MAM.  The 
second ion transition will be the qualifier ion, which is used to confirm that the 
correct target compound has been correctly identified. 
 Time (minutes) % Mobile Phase A  
Methanol with  
0.1% formic acid  
% Mobile Phase B  
MilliQ water with 
0.1% formic acid  
0.00 – 2.00 20 80 
2.00 – 3.00 50 50 
3.00 – 3.80 80 20 
3.80 – 10.00 100 5 
10.00 25 75 
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Table 4: MRM transition ions to identify heroin metabolites and respective internal 
standards 
Substance  Transition Mode 1 
Quantifying Ion 
(amu) 
Transition Mode 2 
Qualifying Ion 
(amu) 
Internal Standard  
Morphine  285.92→152.00  285.92→165.00  Morphine-D3  




461.88→199.00  461.88→286  Morphine-6-
glucuronide-D3  
Morphine-D3  288.96→152.00  288.96→201.00   
6- Monoacetylmorphine -
D3 
330.97→165.00  330.97→211.00   
Morphine-6-
glucuronide-D3  
464.88→201.00  464.88→289.00   
 
2.8   Preparation of Calibrators and QC Samples in 
Hair 
Drug free calibrator and quality control (QC) hair samples were prepared using 
hair obtained from rats without oxycodone or heroin.  
2.8.1 Trial 1: Oxycodone 
A methanolic mixed stock solution containing oxycodone, noroxycodone, and 
oxymorphone was prepared. To twenty milligrams of finely cut hair roots from the 
negative control rats in 10-mL borosilicate glass tubes, twenty-five microlitres of 
working methanolic mixed calibrator standard solutions (0.625 to 5.00 mg/L) 
were added to result in concentrations of 0.78 to 6.8 ng/mg of hair. To each 
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sample, twenty-five microlitres of internal standard (3.3 mg/L deuterated 
oxycodone-D6 in methanol) was also added.  
Separate ampoules of drug solutions were used to prepare QC samples 
solutions. Twenty-five microlitres of mixed QC solutions containing oxycodone, 
oxymorphone and noroxycodone at concentrations of 0.8, 1.6 and 3.2 mg/L in 
methanol were added with twenty-five microlitres of internal standard to twenty 
milligrams of prepared blank hair to yield QC samples containing a mixture of all 
three analytes with concentrations of 1, 2 and 4 ng/mg in hair. 
2.8.2 Trial 2: Heroin 
Twenty-five microlitres of acetonitrile working solutions of 6-MAM and morphine 
(0.25 to 4.0 mg/L; 0.0625 to 1.0 mg/L, respectively) were added to twenty 
milligrams of finely cut hair roots to yield concentrations of 0.31 to 5.0 ng/mg and 
0.08 to 1.25 ng/mg of hair respectively. Twenty-five microlitres of internal 
standard (2.5 mg/L deuterated internal standard, 6-MAM-D3 and morphine-D3 in 
acetonitrile) were also added to each sample.  
Twenty-five microlitres of mixed QC solutions prepared at concentrations of 0.16, 
0.32 and 0.64 mg/L of morphine and 0.64, 1.28 and 2.56 mg/L of 6-
monoacetylmorphine were added with twenty-five microlitres of internal standard 
to twenty milligrams of prepared blank hair samples to yield a set of three QC 
samples with concentrations of 0.2, 0.4 and 0.8 ng/mg morphine and 0.8, 1.6 and 
3.2 ng/mg 6-monoacetylmorphine in hair, respectively. A fourth QC sample was 
prepared at a concentration of 2.5 ng/mg 6-MAM in hair with no morphine 




2.9  Preparation of Hair Sample  
Collected hair roots from exhumed rats in both trials were treated with the same 
method as described for blank hair samples. Twenty-five microlitres of internal 
standard (either 3.3 mg/L of oxycodone-D6 in methanol or 2.5 mg/L 6-MAM-D3 
and morphine-D3 in acetonitrile) was added to each sample. All hair samples 
were mixed with a vortex mixer while the solvent evaporated at room 
temperature.  
Hair samples were digested with the addition of 0.5 mL of methanol: water: 
formic acid (25:74:1; v/v/v), vortexing for 1 minute and sonication in a warm water 
bath for 24 hours at 37˚C.  After sonication samples were centrifuged at 2600 x g 
for 10 min (Model 225A, Fisher Scientific, Pittsburgh, PA) and three hundred 
microlitres of the extract was filtered through 0.45 μm 4 mm Teflon syringe filters 
(National Scientific, Rockwood, TN) and analysed by UPLC-MS/MS.  
Calibration standards and QC samples were analysed with each set of samples, 
with an internal standard curve constructed using linear regression. The limit of 
detection (LOD) was defined as a signal to noise (S/N) ratio of 3:1, while the 
lower limit of quantification (LOQ) was defined by the lowest calibrating standard. 
The precision and accuracy of calibrating standards and QC samples was within 
20% of the target value. 
 
2.10 Preparation of Liver Samples 
Two grams of liver was homogenized in 3.0 mL of normal saline (0.9 g/100mL 
NaCl in deionised water) and centrifuged for 30 min at 3600 x g. The supernatant 
of each sample was analysed for the presence of either oxycodone and selected 
metabolites or heroin metabolites by UPLC-MS/MS after sample extraction.  
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Supernatants of the drug-free livers were utilised in the method development and 
quantification process as blank matrices for calibrators and both negative and 
positive controls. 
 
2.11 Liver Extraction Development 
2.11.1 Trial 1: Oxycodone  
Various sample preparation techniques were investigated after a review of the 
available literature, including liquid-liquid extraction, and protein precipitation. 
Method I: Liquid-liquid extraction 
Method I was adapted from Koves and Wells (1985) for basic drugs in 
postmortem blood. Drug-free or blank supernatant samples of 1 mL were spiked 
with 25 μL of 10 mg/L solution of oxycodone, oxymorphone, and noroxycodone 
and 25 μL of internal standard solution (3.3 mg/L oxycodone-D6) and vortexed. 
Five millilitres of hexane and 200 µL of 6 M NH4OH were added to each sample, 
vortexed for 30 sec, shaken for 10 min, and centrifuged for 20 min at 3100 x g. 
The supernatant was discarded and 2 mL of 1 M H2SO4 was added to the 
hexane layer. Samples were then vortexed, centrifuged, and the hexane layer 
was discarded. One drop of bromothymol blue indicator solution was added to 
the remaining acidic aqueous layer which was made alkaline with 5 M NaOH 
(drop-wise addition until basic) and 1.5 mL of hexane was added. After vortexing 
and centrifuging for 5 min at 3100 x g, the hexane layer was transferred and 
dried down at room temperature under nitrogen. Samples were reconstituted in 
300 μL of mobile phase and analysed using UPLC-MS/MS. 
Method II: Liquid-liquid extraction 
Method II was adapted from Cheremina et al. (2005) for oxycodone and 
noroxycodone in human plasma. Spiked 1 mL supernatant samples, prepared as 
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described above, were vortex mixed with 1.0 mL of 1M NaOH and 4.0 mL of 
diethyl ether. Samples were capped, shaken for 10 min, and then centrifuged at 
3100 x g for 20 min. The organic layer was transferred and evaporated under 
nitrogen at room temperature. Samples were reconstituted in 300 μL of mobile 
phase and analysed using UPLC-MS/MS. 
Method III: Liquid-liquid extraction 
Method III was adapted from Adams, Pieniaszek, Gammaitoni, and Ahdieh 
(2005) for oxymorphone in human plasma. Spiked 1 mL supernatant samples, as 
described above, were vortex mixed with 1 mL of 0.1 M NaOH and 4.0 mL 
dichloromethane (DCM). Samples were then capped, shaken for 10 min and 
centrifuged at 3100 x g for 20 min. The organic layer was transferred and 2 mL of 
0.5 M sulfuric acid was added. After mixing and centrifugation, the organic layer 
was discarded and 400 μL of 6 M NH4OH and 4 mL of DCM were added to the 
aqueous layer. Samples were then vortexed and centrifuged again and the 
organic layer was collected and evaporated under nitrogen at room temperature 
before reconstituted in 300 μL of mobile phase.  
Method IV: Protein precipitation 
Method IV was adapted from Edwards and Smith (2005) for oxycodone in rat 
serum. Spiked 1 mL supernatant samples were vortexed while 50 μL of 6 M 
NH4OH and 1 mL of acetonitrile were added. Diethyl ether (4 mL) was added to 
the acetonitrile-supernatant mixture, vortexed, and centrifuged at 3100 x g for 20 
min. The ether was transferred and evaporated under nitrogen before 
reconstituted in 300 μL of mobile phase. 
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Method V: Protein precipitation 
Spiked 1 mL supernatant samples were precipitated with 3.0 mL acetonitrile 
while vortexing then sonicated for 20 min and centrifuged at 3100 x g for 20 min. 
The liquid fraction of the samples was transferred and dried down under nitrogen 
before reconstitution in 300 μL of mobile phase.  
2.11.2 Trial 2: Heroin 
After a review of the current literature regarding the extraction of heroin 
metabolites, specifically morphine and 6-MAM, the following solid-phase 
extraction and liquid-liquid extraction methods were examined. 
Method I: Solid Phase Extraction (SPE) 
Method I was adapted from United Chemical Technologies Product Application 
Guide (2008) for opiates in whole blood for GC-MS. Spiked supernatants were 
analysed for morphine, 6-monoacetylmorphine and morphine-3-glucuronide 
using 200 mg/3 mL EZ-Extract CSDAU203 (octyl-benzyl sulfonic acid) 
(Diagnostix, Mississauga, ON). The original application guideline analysed 
extracted samples on the GC-MS, thus the method was adapted for extract 
analysis on the UPLC-MS/MS and steps pertaining to sample derivatization and 
volumes of extraction solvents were omitted and/or adjusted.  
One of three sample preparation procedures was examined: A) To 1 mL of liver 
supernatant, 3 mL of acetonitrile was added with vortexing to precipitate proteins. 
Samples were centrifuged and the acetonitrile was transferred and evaporated to 
approximately 0.5 mL. Four millilitres of 0.1 M phosphate buffer (pH 6.0) was 
added to the extract. B) Either 3 mL of distilled water or C) 3 mL of 0.1 M 
phosphate buffer was added to 1 mL of liver supernatant and the remaining 
procedure outlined above repeated.  
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Cartridges were conditioned with 3 mL of methanol, 3 mL distilled H2O, and 1 mL 
of 0.1 M phosphate buffer (pH 6.0). The sample was added to the cartridge then 
washed with 3 mL of distilled H2O, 3 mL of 100 mM acetate buffer (pH 4.0), and 
then 3 mL methanol. The cartridge was dried with compressed air for 5 min and 
heroin metabolites were eluted with 4 mL of dichloromethane: isopropanol: 
NH4OH (78:20:2, v/v/v). The eluent was dried under nitrogen and reconstituted in 
200 μL mobile phase. 
Method II: SPE 
Method II was adapted from Rook, Hillebrand, Rosing, van Ree, and Beijnen 
(2005) for the quantification of heroin and its metabolites in human plasma by 
HPLC-MS/MS. Spiked supernatants were analysed for morphine, 6-MAM and 
morphine-3-glucuronide using a mixed mode sorbent column, Oasis MCX 
(Waters, Mississauga, ON). Columns were conditioned with 3 mL of methanol,  
2 mL of distilled water, followed by 2 mL of 10 mM citrate buffer, pH 3.0. Saline 
supernatants were then loaded onto the column and washed with 1 mL of water 
adjusted to pH 3.0 with acetic acid and dried down for 1 min with compressed air. 
Analytes were eluted with 1.5 mL of 0.5% ammonium acetate in methanol and 
evaporated to dryness and reconstituted in 200 μL mobile phase. 
Method III: SPE 
Method III was adapted from Oasis Product Application Guide (2008) for 
morphine in rat plasma. Oasis MCX columns were conditioned with 1 mL of 
methanol and 1 mL distilled water before samples were loaded and washed with 
1 mL of distilled water and 0.5 mL of 0.1 M HCl. Columns were dried with 
compressed air for 2 min, rinsed with 1 mL of methanol and dried again for 4 min 
before the sample was eluted with 3 aliquots of 250 μL of acetonitrile: 
isopropanol: ammonia (38:57:5, v/v/v), evaporated to dryness and reconstituted 
in 200 μL mobile phase. 
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Method IV: SPE 
Method IV was adapted from an Oasis Product application guide (2008) for 
morphine in rat plasma. Oasis HLB columns were conditioned with 1 mL of 
methanol and 1 mL distilled water before samples were loaded and washed with 
1 mL of methanol: distilled water (5:95, v/v). The column was dried with 
compressed air for 2 min before the sample was eluted with 3 aliquots of 250 μL 
of acetonitrile: isopropanol: formic acid (40:58:2, v/v/v), evaporated to dryness 
and reconstituted in 200 μL of mobile phase. 
  
2.12  Soil Extraction Experiment 
Soil from beneath each carcass was collected and stored at -20˚C until analysis. 
Soils were analysed for the presence of oxycodone and selected metabolites or 
heroin metabolites. Soil was weighed (1.0 gram), dissolved in 1 mL of deionised 
water or 0.1 M phosphate buffer (pH 6.0), spiked with 25 μL of internal standard 
solution, and sonicated at 37̊C in capped culture tubes overnight. The 
supernatant was collected after samples were centrifuged at 1000 x g for 15 min. 
All samples were extracted twice to ensure the highest recovery possible.  
Various organic solvents were chosen to try to maximize the extraction potential. 
Dichloromethane, ethyl acetate, or diethyl ether (3 mL of each solvent) was 
added to each sample. The tubes were vortex mixed for 60 sec and centrifuged 
at 2600 x g for 15 minutes. The organic layer was then collected and evaporated 
in a Savant SC210A SpeedVac Concentrator (Thermo Electron Corporation, 
Asheville, NC) at medium dry rate and reconstituted in 300 μL of mobile phase 
and analysed on the UPLC-MS/MS. The remaining supernatant was made 
alkaline with the addition of 100 μL of 6 M NH4OH, vortexed and either 3 mL of 
DCM, diethyl ether, or ethyl acetate was added to each tube to be re-extracted, 
dried down and reconstituted. The organic layer of the basic fraction was then 
analysed on the UPLC-MS/MS for oxycodone and selected metabolites or 
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morphine and 6-MAM. Ethyl acetate showed the highest recovery based on peak 
area for all analytes and was chosen as the extract solvent.  
 
2.13 Statistical Analysis 
Statistical analysis was conducted using Genstat© 9th edition and SPSS® 13th 
edition statistical packages. Linear regression was used to determine 
relationships between variables of drug concentration and interment period.  
One-way ANOVA analysis determined differences between the soil and tissue 










3.0   Capillary Electrophoresis-Mass Spectrometry 
(CE-MS) Method  
Consistent separation was achieved with the CE-MS for oxymorphone, 
oxycodone, and noroxycodone (retention times: 5.46; 5.69; 6.41 min 
respectively; Figure 4) with a total run time of ten minutes. An ultraviolet (UV) 
diode array detector was initially used in conjunction with the MS; however the 
capillary experienced a high rate of breakage at the non-silanated portion of the 
capillary, which served as a window for the UV detector. To extend the life of the 
capillary, the UV detector was by-passed, decreasing the tension placed on the 
non-silanated portion of the capillary and routed directly to the MS detector.  
Due to the use of a single quadrupole, collision induced fragmentation was 
required to produce a unique fragmentation pattern to confirm the presence of 
oxycodone, however consistent fragmentation was not achieved. Sodium and 
water adducts were produced, however due to the lack of sensitivity and the 
other technical difficulties related to the nitrogen generator required to operate 





 Figure 4: Total ion electropherogram of oxymorphone, oxycodone and noroxycodone 
standards in 25 mM ammonium acetate, pH 9 with sheath liquid of water: methanol 
(50:50, v/v) with 1% formic acid. The sample was electrokinetically injected by applied 
voltage for 10kV for 20 s, with an applied voltage of 27 kV. 
 
3.1   Ultra-Performance Liquid Chromatography-
Tandem Mass Spectrometry (UPLC-MS/MS) 
Method Validation  
After optimization of the extraction and instrumental analysis on the UPLC-
MS/MS, the methods for oxycodone and heroin analysis were validated both in 
hair and liver matrices.  
3.1.1  Linearity 
Calibration curves were obtained by analyzing drug-free hair roots or liver 
extracts fortified with working calibrator solutions. Calibration curves were 
constructed using a non-weighted linear regression based on 5 calibrator peak 
area ratios. The limit of quantification was defined by the lowest calibrator for 
each analyte with a QC precision and accuracy within 20%, while the limit of 
    
    








    
    
    
    







    










detection had a minimum signal to noise ratio of 3:1.  Intraassay linearity was 
assessed by analysing five sets of calibrators on one occasion.  Interassay 
linearity was assessed by analysing different sets of calibrators on five separate 
occasions.  
3.1.2  Accuracy and precision 
To assess accuracy and precision, multiple QC samples at low, medium and 
high concentrations were analysed on five separate runs. Accuracy is a 
measure of how close the calculated value is to the expected value, expressed 
as a percentage (Accuracy = (mean conc. – nominal conc.)/ nominal conc. x 
100%). Precision is defined as the ability of a measurement to be consistently 
reproduced (Precision = (SD of mean/mean) x 100%). The acceptance criteria 
of precision and accuracy were less than 20% deviation.  
3.1.3  Matrix effects 
To determine any ion-suppression and extraction efficiency, three sets of 
samples were prepared as follows: set 1 was neat solutions of the standards, 
dried down and reconstituted in mobile phase; set 2 consisted of blank hair or 
liver samples which were extracted, then fortified with QC and internal standard 
solutions; and set 3 composed of blank hair or liver samples fortified with QC 
and internal standard solutions added before extraction. Each set had five 
replicates and extraction efficiency was calculated as the ratio of the average 
peak area in set 3 to 2, expressed as a percentage. Matrix effect was defined as 
the percentage ratio of the average peak areas for sets 2 and 1.  
3.1.4 Extract stability 
Stability of extracted samples were evaluated after freeze-thaw with a full set of 
calibrators and QC samples, which consisted of freezing at -20°C after analysis 
for two weeks and reanalyzing the samples after unassisted thawing at room 
temperature. To confirm the within assay reproducibility of the UPLC-MS/MS, a 
calibrator was reinjected at the end of each assay.   
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3.2   Method Validation for Oxycodone 
Multiple ion transition monitoring (MRM) in electrospray ionization was selected 
for the identification and quantification of oxycodone and its metabolites, 
noroxycodone and oxymorphone. One unique ion transition for each analyte was 
chosen; the most abundant ion transition that did not involve the loss of water 
(m/z = 18) was chosen.  
All analytes eluted within four minutes, however the gradient program was run for 
10 minutes to allow for column equilibration before the next injection. At least five 
different blank hair, liver and soil samples were analysed to determine that there 
were no interferences with the analytes of interest. Seven other opiates (codeine, 
hydrocodone, meperidine, methadone, morphine, 6-MAM, and hydromorphone) 
were also analysed to demonstrate that the ion transitions and retention times 
were specific to the analytes of interest.  Initial method development included the 
use of oxymorphone-D3 and noroxycodone-D3 as internal standards, however the 
recovery and response of these deuterated internal standards were not 
consistent among different spiked blank-livers, thus oxycodone-D6 was utilised as 
an internal standard for all three analytes. 
3.2.1 Hair Validation 
Hair samples were analysed for the presence of oxycodone, noroxycodone and 
oxymorphone. Hair root samples were briefly rinsed in approximately 2 mL of 
HPLC grade dichloromethane prior to extraction. The rinse solutions for the 
samples were dried down, reconstituted in mobile phase and analysed on the 
UPLC-MS/MS to demonstrate that there was no external contamination of 




Figure 5: Extracted ion chromatograms of dried down and reconstituted rinse solution. 
Channel 322.11/247.2 for oxycodone-D6 (RT: 3.64 min); 316/241.11 for oxycodone 
(RT: 3.64 min); 305/231.1 for oxymorphone-D3 and noroxycodone-D3 (RT: 3.54 and 
2.45 min, respectively); 302.05/227.1 for oxymorphone and noroxycodone (RT: 3.54 
and 2.45 min, respectively).  
 
The hair method was linear (r2 > 0.985) for oxycodone, oxymorphone, and 
noroxycodone from 15.6 to 125 ng/mL which for a ten-milligram sample of hair is 
equivalent to 0.78 - 6.25 ng/mg. The LOQ was the lowest point of the calibration 
curve (15.6 ng/mL) and the LOD was 0.78 ng/mL or 0.39 ng/mg of hair. The 
percentage deviation for the calibrators range did not exceed ± 20%. Both intra- 
and interassay linearity were assessed as described in Section 3.1.1 (Table 5, 
Table 6).  
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Table 5: Intraassay linearity assessed with five different blank hair matrices for 




Slope Intercept r2 
Oxycodone 3.64 2.54 (±6.83 x10-1) -4.28 (± 2.75 x101) 0.993  (± 1.25 x10-2) 
Oxymorphone 3.54 1.88 (±1.08 x10-1) -0.44 (± 2.39 x101) 0.995  (± 6.30 x10-3) 
Noroxycodone 2.45 1.39 (±2.59 x10-1)  6.23 (± 6.71 x101) 0.999  (± 5.64 x10-3) 
Calibration range for all analytes: 0.78 to 6.25 ng/mg.  Mean (± S.D.) 
 
Table 6: Interassay linearity assessed over five different assays in hair for oxycodone 
and selected metabolites 
Analyte Slope Intercept r2 
Oxycodone    
Blank Hair 1 2.19 -6.89 0.999 
Blank Hair 2 2.69 1.61 0.987 
Blank Hair 3 2.10 1.50 0.999 
Blank Hair 4 2.72 1.69 1.00 
Blank Hair 5 2.43 4.54 0.986 
Mean (± S.D.) 2.43 (± 2.81x10-1) 0.487 (± 4.32x101) 0.994 (± 7.05x10-3) 
Oxymorphone 
Blank Hair 1 1.88 0.799 1.00 
Blank Hair 2 1.76 -2.77 0.995 
Blank Hair 3 1.81 -1.50 0.999 
Blank Hair 4 1.99 -3.20 0.988 
Blank Hair 5 1.78 1.09 0.989 
Mean (± S.D.) 1.84 (± 9.49x10-2) -1.120 (± 1.98x101) 0.994 (± 5.54x10-3) 
Noroxycodone 
Blank Hair 1 1.64 0.126 0.999 
Blank Hair 2 1.11 12.076 0.986 
Blank Hair 3 1.65 -8.174 0.987 
Blank Hair 4 1.59 0.717 0.996 
Blank Hair 5 1.23 12.010 0.996 
Mean (± S.D.) 1.44 (± 2.52x10-1) 3.351 (± 8.68x101) 0.993 (± 5.89x10-3) 
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To evaluate intraassay accuracy and precision, three QC samples at various 
concentrations within the calibration curve were prepared and analysed with 
each assay. The accuracy and precision data are summarized in Table 7. 
Table 7: Intraassay and interassay accuracy and precision of QC samples at various 
concentrations in hair for oxycodone and selected metabolites 










QC Low 1.0 82-97 8.6 80-93 6.5 
QC Med 2.0 80-118 18.0 81-103 10.7 
QC High 4.0 80-113 15.0 92-108 8.0 
Noroxycodone 
QC Low 1.0 91-103 4.8 81-112 12.0 
QC Med 2.0 89-114 11.5 83-95 6.6 
QC High 4.0 92-114 8.7 95-120 10.2 
Oxymorphone 
QC Low 1.0 81-109 11.5 88-104 6.5 
QC Med 2.0 84-102 9.5 82-93 5.1 
QC High 4.0 97-114 7.6 104-118 4.4 
 
Ion enhancement was observed as the matrix effect for oxycodone, 
noroxycodone, oxymorphone and the internal standard, oxycodone-D6 ranged 
from 130% (±11.5), 115% (±6.1), 103% (±4.1) and 113% (±1.1) respectively. The 
extraction efficiency for oxycodone, noroxycodone, oxymorphone and the internal 




3.2.2 Liver Validation  
The analytical extraction chosen for liver sample analysis was protein 
precipitation by acetonitrile. The limit of detection (LOD) and lower limit of 
quantification (LOQ) were 3.9 ng/mL and 7.9 ng/mL and the calibration curves 
were linear over a range from the LOQ to 125 ng/mL. A one-gram sample of liver 
was homogenized with 1.5 mL of saline and 0.5 mL of supernatant was spiked 
and extracted, this calibration curve is equivalent to 5.85 to 187.5 ng/g liver. The 
percentage deviation for the calibrators range did not exceed ± 20%.  
The mean calibration curve slope and intercept and mean retention time for each 
analyte over 5 batches in liver are given in Table 8. All analytes were calibrated 
using non-weighted linear regression with the origin excluded.  
 
Table 8: Intraassay linearity assessed with five different blank liver matrices for 




Slope Intercept r2 
Oxycodone 3.64 0.954 (±  1.25 x10-3) 0.348 (±  9.17 x 10-4) 0.999 (±  2.80 x10-4) 
Oxymorphone 3.54 0.647 (±  1.02 x10-2) 0.627 (±  4.55 x10-1) 0.992 (±  5.59 x10-4) 
Noroxycodone 2.45 0.512 (±  3.28 x10-1) 0.278 (±  6.10 x 10-1) 0.997 (±  1.93 x10-3) 
Calibration range for all analytes = 5.9 to 188 ng/g. Mean (± SD) 
 
Interassay linearity was assessed over 6 different days with 6 different sources of 
blank matrix. The linearity data is summarized in Table 9.  
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Table 9: Interassay linearity assessed over six different assays in liver for oxycodone 
and selected metabolites  
Analyte Slope Intercept r2 
Oxycodone 
Blank Liver 1 0.852 2.390 1.00 
Blank Liver 2 0.956 0.469 1.00 
Blank Liver 3 0.969 0.699 0.999 
Blank Liver 4 0.968 0.111 1.00 
Blank Liver 5 0.942 1.150 0.999 
Blank Liver 6 0.833 2.282 0.999 
Mean (± SD) 0.920 (±  6.11x10-2) 1.183 (± 9.54x10-1) 1.00 (± 5.48x10-4) 
Oxymorphone 
Blank Liver 1 0.632 0.627 0.999 
Blank Liver 2 0.663 -0.027 0.998 
Blank Liver 3 0.636 0.768 0.999 
Blank Liver 4 0.648 0.351 0.999 
Blank Liver 5 0.640 -0.275 1.00 
Blank Liver 6 0.444 4.04 0.994 
Mean (± SD) 0.611 (±  8.23x10-2) 0.914 (±  1.58) 0.998 (±  2.14x10-3) 
Noroxycodone 
Blank Liver 1 0.453 1.787 0.996 
Blank Liver 2 0.493 0.834 0.998 
Blank Liver 3 0.495 0.555 0.998 
Blank Liver 4 0.569 -0.576 0.994 
Blank Liver 5 0.492 0.297 0.998 
Blank Liver 6 0.198 4.00 0.999 




For intraassay accuracy and precision, quality control (QC) samples at various 
concentrations within the dynamic range of the calibration curve for each analyte 
were run with five replicates in one assay. For interassay accuracy and precision, 
each QC sample was run once each assay on five different occasions (Table 10). 
Table 10: Intraassay and interassay accuracy and precision of QC samples at various 
concentrations in liver for oxycodone and selected metabolites 
Analyte Concentration  Intra Assay (n = 5) Inter Assay (n = 1) 









QC Low 30 96-106 4.6 91-104 5.5 
QC Med 75 83-105 10.4 98-106 3.4 
QC Med-High 98 89-117 10.9 - - 
QC High 150 90-102 6.1 84-115 11.1 
Noroxycodone 
QC Low 30 95-101 2.7 91-99 3.2 
QC Med 75 102-104 1.4 85-97 4.7 
QC Med-High 98 78-117 14.9 - - 
QC High 150 91-114 9.6 89-107 6.4 
Oxymorphone 
QC Low 30 98-116 7.5 86-96 4.5 
QC Med 75 98-103 3.3 91-98 2.8 
QC Med-High 98 88-115 11.9 - - 
QC High 150 99-101 1.2 90-106 7.0 
 
The matrix effect for each analyte and internal standard were assessed at three 
concentrations (as described above at 30, 75 and 150 ng/mg). Ion suppression 
was observed as the matrix effect for oxycodone ranged from 85% (±11); for 
oxymorphone from 49% (±8); and for noroxycodone from 40% (±9); for all 
concentrations. The extraction efficiency for oxycodone, noroxycodone, 
oxymorphone and the internal standard, oxycodone-D6 was 90% (±7.8), 86% 
(±7.3), 84% (±13), and 99% (±4.9), respectively. 
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3.2.3 Oxycodone in Soil 
The soil directly beneath the carcasses, otherwise known as grave soil, was 
collected and analysed to determine if the presence of oxycodone and its 
metabolites could be determined. A qualitative method was validated for the 
determination of oxycodone and oxymorphone in soil; however the method used 
was not successful in the extraction of noroxycodone. Blank soil samples fortified 
with the three analytes were extracted and only oxycodone and oxymorphone 
were detected by UPLC-MS/MS. Both enzymatic and liquid-liquid extraction 
techniques were examined. The extraction solvent that showed the highest 
recovery from spiked samples of blank soil was ethyl acetate. The analysis of soil 
for the presence of drugs can be beneficial if the body is removed by scavenging 
or decomposition has proceeded to the stage where hair or bones are not 
available for analysis (Dunnett, Ashton, & Osselton 1979).  
A modified validation procedure was utilised for this method as it was used to 
only determine the presence/absence of oxycodone in soil (Peters, Drummer, & 
Musshoff, 2007). Six different blank soil samples were analysed, with and without 
the addition of internal standards to check for the absence of interfering signals. 
Blank soil samples were spiked with known amounts of oxycodone, 
oxymorphone and noroxycodone at concentrations ranging from 0.78 to 2.5 ng/g 
and analysed along with a negative control sample and three positive control 
samples (1.56, 3.125 and 6.25 ng/g). The samples were analysed and a limit of 
detection was determined to be 6.25 ng/g for oxycodone and oxymorphone, 
however a linear response (r2 > 0.985) could not be reliably achieved. Thus as a 
quantitative result would not be reflective of the amount of oxycodone 
administered or present in the body at the time of death, a simplified qualitative 
method was developed. Ten positive control samples were spiked, extracted and 
analysed at a concentration of 6.25 ng/g of soil (Figure 6).  
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The internal standard, oxycodone-D6 had an extraction recovery of 38% (±6.9) 
while oxycodone and oxymorphone had extraction recoveries of 25% (±7.8) and 
18% (±4.7). The positive controls were identified as oxycodone and 
oxymorphone positive in all ten samples and had an average response ratio of 
158.3 (±22.1) with a coefficient of variation of 14.0% for oxycodone. The average 




Figure 6: Total ion chromatograms and extracted mass chromatograms obtained from 
blank soil fortified with 6.25 ng/g of oxycodone (RT: 3.52 min, m/z 316/241.1) and 
oxymorphone (RT: 3.52 min, m/z 302.05/231.1).  Internal standard: oxycodone-D6 (RT: 
3.57 min, m/z 322.11/247.2) 
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3.3   Method Validation for Morphine and   
 6-Monoacetylmorphine 
The two most abundant MRM transitions for morphine and 6-
monoacetylmorphine (6-MAM), excluding the loss of water, were chosen to 
quantify and qualify each analyte (Figure 7, Figure 8). Mass spectrometric 
conditions for each MRM transition were individually optimized. The mean 
relative abundance ratios of the two MRM transitions for morphine averaged 1.00 
in all calibrators, with percent coefficient of variance (%CV) of less than 9% 
observed over five different assays. The mean relative abundance ratio for 6-
MAM averaged 1.39 in calibrators with a %CV of less than 10% observed over 
five different assays.  
All analytes eluted within four minutes and the analytical run time was ten 
minutes. The flow was adjusted after the elution of the last analyte (6-MAM) to 
allow the column to re-equilibrate and fully elute any other potential interfering 
compounds from the column before the next injection.  
Blank liver and hair from five different sources had minimal interferences with the 
analytes of interest, with the exception of morphine-3-glucuronide and its internal 
standard morphine-6-glucuronide-D6. Morphine-3-glucuronide and the deuterated 
internal standard were added to all calibrators, however it was not consistently 
detected by any of the extraction methods and it was excluded from the study. 
Validation of the method was completed with a second set of working standard 
solutions which excluded the glucuronide standards to eliminate the possibility 
that the glucuronide moiety could be cleaved during the extraction process to 
produce morphine, thereby possibly resulting in an increased morphine and/or 






   
  
  
Figure 7: Mass spectra of morphine obtained from a MRM autotune. A) Parent mass of 
285.92 and B) Daughter masses of 152.0 and C) 165.0 with a cone voltage of 50 V and 








































Figure 8: Mass spectra of 6-MAM obtained from a MRM autotune. A) Parent mass of 
327.87 and B) Daughter masses of 165.0 and C) 211.0 with a cone voltage of 52 V 



































3.3.1 Hair Validation 
For morphine and 6-MAM in hair, two transition ions were monitored for all 
analytes and internal standards. Non-weighted linear regression using least 
squares regression was used to calculate the slope, intercept and coefficient of 
correlation. Linear regressions using the primary ion and the secondary ion were 
calculated (Table 11). Although all the intraassay coefficients of correlation were 
equal to or greater than 0.999 for both modes of quantification, the interassay 
variability (as measured by the standard deviation) was greater and the 
coefficient of correlation was not consistently greater than 0.985 when using the 
secondary ion; thus case and quality control samples were quantified using the 
primary transition ion response ratio and the secondary transition ion as a 
qualifier (Table 11 and Table 12).  
 
Table 11: Intraassay linearity assessed with five different blank hair matrices for 
morphine and 6-MAM 
Analyte Slope  Intercept r2 
Morphine    
Primary ion 7.27 (± 0.31) 3.36 (± 1.30)  0.999 (± 0.001) 
Secondary ion 8.28 (± 0.46) 1.14 (± 4.20) 1.00 (± 0.002) 
6-MAM    
Primary ion 16.16 (± 1.30) 0.55 (± 0.86) 1.00 (± 0.001) 
Secondary ion 24.08 (± 2.50) 52.95 (±13.03) 0.999 (± 0.001) 
Calibration range for morphine = 0.08 to 1.25 ng/mg; for 6-MAM = 0.31 to 5.0 ng/mg.   Mean (± SD) 
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Table 12: Interassay linearity assessed with five different blank hair matrices for morphine and 6-MAM 
Analyte Slope Intercept r2 
 1st ion 2nd ion 1st ion 2nd ion 1st ion 2nd ion 
Morphine       
Blank Hair A 6.87 9.60 5.39 -19.41 1.00 0.972 
Blank Hair B 6.60 8.27 6.05 5.01 0.992 0.975 
Blank Hair C 7.90 8.34 0.68 4.55 1.00 0.957 
Blank Hair D 7.69 7.72 1.32 2.03 1.00 0.959 
Blank Hair E 7.72 7.46 0.98 8.26 1.00 0.987 
Mean (± SD) 7.36 (± 0.58) 8.28 (± 0.83) 2.88 (± 2.61) 0.088 (± 11.12) 0.998 (± 0.004) 0.970 (± 0.012) 
6-MAM       
Blank Hair A 15.90 19.57 11.25 311.19 0.997 0.884 
Blank Hair B 14.78 20.17 40.92 78.69 0.989 0.983 
Blank Hair C 16.90 20.88 -30.30 93.46 1.00 0.996 
Blank Hair D 15.88 28.25 6.67 -12.38 0.999 0.991 
Blank Hair E 17.03 27.03 -15.08 52.03 1.00 0.983 
Mean (± SD) 16.10 (± 0.91) 23.18 (± 4.12) 2.69 (± 27.18) 104.60 (± 122.40) 0.997 (± 0.006) 0.967 (± 0.047) 
 62 
To quantify morphine and 6-MAM in hair and liver, all calibrators used in each 
calibration were within ± 20% of their target concentrations. The relative 
abundance ratios of the qualifier MRM transition ion to quantification MRM 
transition ion for morphine and 6-MAM were calculated based on the calibrators. 
Morphine has a relative abundance ratio of 1.0 and 6-MAM has an abundance 
ratio of 1.39. The internal standards had a relative abundance ratio of 1.02 for 
morphine-D3 and 2.29 for 6-MAM-D3. All QC and case samples had a minimum 
relative abundance of ± 20% for the analyte to be considered detected.  
The method was evaluated with five replicates of low, medium, and high 
concentration quality control (QC) samples for each analyte in one assay for 
intraassay accuracy and precision. Interassay accuracy and precision were 
evaluated once with low, medium, and high concentration quality control samples 
over 5 different assays (Table 13).  
To evaluate the in-vitro stability of 6-MAM, an additional QC sample in hair was 
made up to contain only 6-MAM at a concentration of 2.5 ng/mg. The absence of 
morphine in the extracted sample demonstrated that 6-MAM was not hydrolyzed 
to morphine during the incubation, extraction and ionization process. Authentic 
samples underwent the same extraction process with a preparatory rinse step. 
Drug free hair samples used to make up calibrators and QC samples were rinsed 
prior to the addition of calibrator, QC, and internal standard solutions. All samples 
were rinsed in approximately 2 mL of HPLC-grade dichloromethane and the 
solutions were dried down and analysed on the UPLC-MS/MS to demonstrate 
that there was no external contamination of collected samples (Table 13).  
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Intraassay (n = 5) Interassay (n = 1) 
Accuracy (%) Precision (%CV) Accuracy (%) Precision (%CV) 
Morphine 
QC Low 0.2 80 - 93 6.7 89 - 94 7.0 
QC Med 0.4 85 - 103 7.8 94 - 108 11.2 
QC High 0.8 83 - 100 9.6 83 - 115 15.1 
QC 6-MAM 0 not detected not detected - - 
6-MAM 
QC Low 0.8 92 - 100 4.0 90 - 100 5.5 
QC Med 1.6 78 - 113 16.8 80 - 115 17.6 
QC High 3.2 93 - 98 2.2 91 - 103 5.5 
QC 6-MAM 2.5 80 - 87 3.7 82 - 120 18.9 
Note: QC 6-MAM contained 2.5 ng/mg of 6-MAM; the sample did not contain morphine. This sample was prepared to 
assess the stability of 6-MAM.
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The extraction efficiency and matrix effect for each analyte and internal standard 
were assessed across all calibrators. The extraction efficiency in hair was 82% 
(±9.4) for morphine; 85% (±6.8) for 6-MAM; 87% (±3.3) for morphine-D3; and 
87% (±5.1) for 6-MAM-D3. Ion suppression was observed in the non-deuterated 
drug standards as the matrix effect for morphine was 85% (±8.3); and 6-MAM 
was 70% (±6.2).  The matrix effect for the internal standards was 116% (±9.6) for 
morphine-D3 and 101% (±3.4) for 6-MAM-D3.  
 
3.3.2 Liver Validation 
The same chromatographic and MS conditions were utilised for the analysis of 
morphine and 6-MAM in liver. Calibration curves utilising the secondary ion as 
the quantification ion for intraassay analysis yielded linear curves with an r2 value 
of 0.996, while the r2 value for the primary ion was 0.983 (Table 14). However, 
interassay testing demonstrated that the use of the primary ion for quantifying 
morphine resulted in a consistent linear curve with an r2 of 0.985 or greater for all 
5 different matrices. Thus the secondary ion was used as a qualifier or 
confirmation ion (Table 15) and the primary ion was the quantifying ion. The 
linearity for 6-MAM was comparable utilising either ion transition as the 
quantifying ion, however as 6-MAM in hair was quantified using the primary ion, 
the same transition ion was selected to quantify 6-MAM in liver, while the second 
ion was used as a qualifying ion. 
Table 14: Intraassay linearity assessed with five different blank liver matrices for 
morphine and 6-MAM 
Analyte Slope  Intercept r2 
Morphine    
Primary ion 0.78 (± 0.41) 4.30 (± 2.90) 0.983 (± 0.006) 
Secondary ion 0.67 (± 0.13) 2.83 (± 1.56) 0.996 (± 0.009) 
6-MAM    
Primary ion 1.54 (± 0.21) -2.50 (± 2.81) 0.999 (± 0.005) 
Secondary ion 1.11 (± 0.20) -3.87 (± 7.61) 1.00 (± 0.005) 
Calibration range for morphine and 6-MAM = 23 to 375 ng/g.   Mean (± SD) 
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Table 15: Interassay linearity assessed with five different blank liver matrices for morphine and 6-MAM 
Analyte Intercept Slope r2 
 1st ion 2nd ion 1st ion 2nd ion 1st ion 2nd ion 
Morphine       
Liver A 0.812 2.587 1.360 0.758 0.987 0.987 
Liver B 18.452 12.449 0.397 0.470 0.985 0.774 
Liver C 1.207 15.611 0.692 0.466 0.987 0.784 
Liver D -1.140 4.607 0.692 0.631 0.997 0.905 
Liver E 1.332 2.158 0.621 0.644 0.983 0.992 
Mean (±SD) 4.132  (± 8.067) 7.482 (± 6.151) 0.7525 (± 0.361) 0.594 (± 0.125) 0.988 (± 5.40x10-3) 0.888 (± 1.06x10-1) 
6-MAM          
Liver A -4.373 -0.675 1.827 1.292 0.985 0.994 
Liver B 5.305 1.911 1.398 1.021 0.997 0.998 
Liver C 3.258 -13.230 1.648 1.178 0.999 0.994 
Liver D -3.780 0.190 1.302 0.973 0.995 0.998 
Liver E -1.050 1.950 1.515 1.112 0.994 0.998 
Mean (±SD) -0.128  (± 4.278) -1.971  (± 6.395) 1.538  (± 0.207) 1.115  (± 0.127) 0.994  (± 5.00x10-3) 0.996  (± 2.00x10-3) 
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The accuracy and precision of the assay were assessed by analysing three QC 
samples at concentrations of 30, 120, and 240 ng/g of both morphine and 6-MAM 
during intra- and interassay linearity testing. For intraassay accuracy and 
precision, the QC samples were run with five replicates in one assay, n = 5. For 
interassay accuracy and precision, the QC samples were run once each assay 
on five different occasions. All QC samples were within 20% of the expected 
concentration (Table 16). 







Intraassay (n = 5) Interassay (n = 5) 
Accuracy (%) Precision 
(%CV) 
Accuracy (%) Precision 
(%CV) 
Morphine 
QC Low 30 90-119 14.3 101-120 9.4 
QC Med 120 82-96 8.0 85-97 8.7 
QC High 240 92-114 11.8 94-99 8.6 
6-MAM 
QC Low 30 80-113 17.2 82-120 18.7 
QC Med 120 116-120 2.0 101-120 8.8 
QC High 240 95-116 10.8 96-117 10.2 
 
Ion suppression was observed with the matrix effect for morphine in liver at 
65.1% (± 3.0) and 55.4% (± 2.5) for morphine-D3. The extraction efficiency of the 
assay for morphine and morphine-D3 was 70.2% (± 13.0) and 59.0% (± 7.0), 
respectively. For 6-MAM and 6-MAM-D3, ion suppression was not as great as the 
matrix effect was calculated to be 94.2% (± 8.3) and 101.0% (± 14.3), 
respectively. The extraction efficiency for 6-MAM and 6-MAM-D3 was 67.9 (± 7.0) 
and 83.1% (± 1.5), respectively. 
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3.3.3 Morphine and 6-Monoacetylmorphine in Soil 
As with the soil extraction method developed for oxycodone and oxymorphone, 
the soil extraction method for heroin metabolites was qualitative only. The same 
procedure for method validation was followed. The limit of detection for morphine 
and 6-MAM was 3.13 ng/g soil. The extraction efficiency for morphine was 25% 
(± 7.8) and 24% (± 5.6) for morphine-D3. The recovery for 6-MAM was 36 (± 10.3) 









4.0  Postmortem Changes of Trial 1: Oxycodone 
The burial trial of 30 rats administered oxycodone for 5 days prior to sacrifice 
consisted of a post burial interval that ranged from 0 to 30 days (Figure 9). With 
each harvest (every 3 days), the state of decomposition steadily progressed 
from the Fresh, Bloated/Inflated, to Deflated or Active Decay stage. At the end of 
the 30 days, the remaining rats had not yet progressed to the Advanced Decay 
or Dried Remains stage (Figure 9, Day 30).  
The first stage (Fresh) was the period between death and initial bloating and 
was observed at the initial harvest (Day 3). At Day 3, the surface soil was 
partially covered with a very thin coat of white fungi, which was not identified 
(Figure 10, Day 3). The carcasses were intact and the organs were bright red in 
colour and solid in texture with liquid in the abdominal cavity resembling blood.  
Between Day 6 and Day 9 all the exhumed carcasses were fully inflated at the 
abdomen and scrotum (Figure 9, Day 6 and Day 9). One of the three carcasses 
exhumed on Day 12 was also observed to be in the second stage of 
decomposition. The degree of inflation from decomposition gases against the 
abdominal walls resulted in displacement of surface soil in one of the 
microcosms and there was a thick white coat of fungus covering the soil above 
the carcass. An incision at dissection to the abdominal cavity resulted in deflation 
of the carcasses. Bloating was not evident on the appendages, however internal 
organs were yellow coloured and the colon and stomach were inflated. 
Translucent yellow liquid in the abdominal cavity was observed and the 
underside of the carcasses exposed to the grave base was darker in colour 


































Day 27   Day 30 
 
Figure 9: Oxycodone treated rats sacrificed and buried in soil microcosms. 
Exhumed carcasses in-situ from Day 0 to Day 30; carcasses harvested every 3 days, n = 3. 
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Day 0    Day 3        Day 6 
 
Day 9    Day 12        Day 15 
 
Day 18   Day 21        Day 24 
 
Day 27   Day 30  
 
Figure 10: Undisturbed grave surface of burial microcosms from Day 0 to 30.  




At Day 12, the carcasses were deflated and the outer epidermal layers were 
sloughing off. Upon exhumation, the arms and tail of the carcasses adhered to 
the grave floor, and the surfaces of the tissue on the abdomen and back of each 
carcass were black in colour.  
It can be observed from Figure 11 in the Day 21 and Day 27 photos, the stomach 
and part of the intestines ruptured and became shrivelled and partially 
dehydrated. The ability to distinguish between internal organs become more 
difficult as the post burial interval increased. At Day 30, the organs became 
liquefied (Figure 11, Day 30). A summary of the stage of decomposition reached 
by the rat carcasses is shown in Table 17.  
 
Figure 11: Internal organs of oxycodone-dosed rats upon exhumation.   
Organs exhibited decomposition changes as the post burial interval increased. 
Discolouration and distension of various internal organs can be observed; liquefaction 







Table 17: Stage of decomposition of oxycodone-dosed rat cadavers by post burial 
interval, n = 3. 
Post Burial 
Interval (Days) 




 Inflated  
  Active 
  Stages were determined by visual observations. 
As the post burial interval increased, the upper and lower surfaces of the 
carcasses became very distinct; the upper surfaces became desiccated and stiff 
while the lower surfaces remained moist and pliable due to the gravitational flow 
of decomposition fluids downwards towards the grave floor (Figure 12). The 
tissue on the lower surface was very fragile and was susceptible to tearing. 
Towards the end of the burial trial, a scalpel was not required to access the 
abdominal cavity.  
 
Figure 12: Upper and lower surfaces of carcass at Day 24.  
The soft and moist lower surface (abdomen) is distinct in texture and more pliable 




The moisture content of the soil increased from approximately 50% water holding 
capacity (WHC) to 60 to 65% over the thirty-day period; however the pH of the 
soil varied over time. The initial 6.8 pH of the soil decreased to 5.2 by Day 27. 
Conversely, liver pH increased as the post burial interval increased from mean 
pH 6.3 to 8.3 by Day 30 (p < 0.001, Figure 13).  
Upon collection, all samples were stored at -20°C until analysis. The pH of liver 
samples collected did not change over time and subsequent analysis did not 
change with 5 freeze-thaw cycles. 
 
Figure 13: The pH of liver was measured upon exhumation.  
ANOVA F(10, 19) = 11.49,  p < 0.001. There was a significant difference between Days 3 
and 15 - 30; 6 and 24 - 30; 9 and 12 to 27 - 30.  
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4.1  Postmortem Changes of Trial 2: Heroin 
During the second burial trial with heroin-administered rats, the post burial 
interval between exhumations was increased from every 3 days to an initial 7 
days and then to every 14 days after the first two weeks to increase the total 
internment period from 30 to 56 days. Rats that were not dosed with heroin were 
designated as control rats; one control was exhumed with every harvest.  
The first set of carcasses exhumed on Day 7 had progressed to the bloat/inflated 
stage of decomposition (Figure 14, Day 7). The carcasses were extensively 
inflated in the abdominal and thoracic cavities, upon dissection the internal 
organs were also inflated with mild discolouration. At Day 14, the carcasses had 
not progressed beyond the bloat/inflated stage (Figure 14, Day 14). 
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Day 0     Day 7 Control    Day 7* 
 
Day 14 Control   Day 14*     Day 28 Control     Day 28*  
 
Day 42 Control   Day 42*     Day 56 Control     Day 56*  
 
Figure 14: Control and heroin-treated rats (*) sacrificed and buried in soil microcosms.  
One control and three heroin-treated carcasses were exhumed at Days 7, 14, 28, 42 and 56. 
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Active decay was observed in carcasses harvested at Day 28 with ruptures and 
tears on the surface of the abdominal cavity, presumably from the pressure of 
putrefactive gases (Figure 15). Disarticulation of the skull was also observed and 
despite ruptures to the abdominal cavity, the thoracic cavity remained intact.  
Figure 15: Internal organs of heroin-treated rats from Day 0 to Day 56. Abdominal 
cavity ruptures were observed from Day 28. 
  
At Day 42, the carcasses were in advanced decay, as the tail and at least one 
limb of each carcass had either fallen off or tore off upon exhumation (Figure 16). 
At Day 56, partial mummification was observed on the upper surface of the 
carcass while the lower portion was moist and marbled in colour. A rupture of the 
abdominal wall exposed the internal organs, which were partially liquefied. The 
stomach and the portions of the large intestines ruptured, releasing its contents 
into the abdominal cavity.  
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Figure 16: Control Rat (10) and Heroin-treated Rat (1) exhumed on Day 42. Ruptured 
abdominal walls exposed internal organs. 
It is important to note that there were no visible differences with respect to the 
rate and nature of decomposition between control and treatment rats throughout 
the decomposition trial (Figure 14). At each harvest, the stage of decomposition 
was visually observed and categorized as either: Fresh, Inflated, Active, or 
Advanced Decay (Table 18). Despite the increased interment period from 30 to 
56 days, the carcasses did not reach the Dried Remains stages of 
decomposition. 
Table 18: Stage of decomposition of control and heroin-dosed rat cadavers by post 
burial interval, n = 1 and n = 3, respectively.  




0 7 14  28  42  56 
Stage of Decomposition 
 
Heroin, n = 3 
Fresh 
 Inflated  
  Active  
    Advanced 
 
Control, n = 1 
Fresh  
 Inflated  
  Active  
   Advanced 
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Both the grave surfaces of the control rat and the heroin-treated rats (n = 3) with 
each harvest exhibited similar growth of white fungus, which was not identified 
(Figure 17). The fungal growth for the second trial followed a similar pattern of 
growth as observed in the first (oxycodone) burial trial (Figure 10). 
 
 
Figure 17: Undisturbed grave surfaces of control and heroin-treated (*) rats (n = 3) from 
Day 0 to Day 56. Carcasses were exhumed at Days 7, 14, 28, 42, and 56. 
 
There was no significant difference in pH between livers collected from control 
and heroin-dosed rats.  There was also no significant difference in the pH of 
livers collected from the initial burial trial and the livers collected in the second 
burial trial (p = 0.819). There was a difference of liver pH over time (p < 0.001) 
with the pH increasing as the burial trial progressed. The soil pH decreased as 
the interment period increased with a sharp drop at Day 14, returning to basal 
levels by Day 56 (p < 0.001).  
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4.2   Detection of Oxycodone in Samples 
Liver samples collected from sequentially harvested exhumed rats were analysed 
for the presence of oxycodone and its major metabolites, noroxycodone and 
oxymorphone. The concentration of oxycodone in liver decreased as the post 
burial interval increased (r2 = 0.48, p < 0.001) (Table 19, Figure 18). 
Oxymorphone concentrations also decreased as the post burial interval 
increased (r2 = 0.47, p < 0.001), however there was no significant difference in 
noroxycodone concentrations. The large standard deviations for noroxycodone 
and oxymorphone liver concentrations reflect the small sample size, n = 3, and 
the drug was not detected in all samples analysed. 
 







Mean (± SD) ng/g 
Oxymorphone 
 
0 21.94 (± 3.01) ND 40.2 (± 5.15) 
3 23.27 (± 5.61) 6.60 (± 11.43) 27.2 (± 7.81) 
6 20.05 (± 4.23) 6.75 (± 11.69) 20.35 (± 5.98) 
9 13.00 (± 1.80) 12.45 (± 10.94) 6.00 (± 10.39) 
12 11.74 (± 1.70) ND 12.60 (± 10.92) 
15 12.49 (± 2.11) ND 6.45 (± 11.17) 
18 9.16 (±0.82) trace ND 
21 8.93 (±0.16) ND trace 
24 10.82 (± 0.40) ND trace 
27 trace ND ND 
30 ND trace ND 
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Figure 18: Oxycodone concentrations (mean) in liver in rats exhumed from burial 
microcosms, n = 3. Burial intervals ranged from 0 to 30 days. 
 
Hair roots from the back of each rat were collected prior to burial. Each rat was 
then buried and exhumed after a number of days. Hair roots collected after 
exhumation were analysed and compared to the hair roots collected from the 
same rat prior to burial. The concentration of oxycodone and its metabolites in 
each sample are given in Table 20. Oxymorphone was detected in liver samples 
while the hair samples examined did not contain oxymorphone at quantifiable 
levels. This may be explained in part by the chemical nature of the drug and the 
fact that oxymorphone is a minor metabolite of oxycodone (Pöyhiä, Olkkola, 
Seppälä, & Kalso, 1991). Noroxycodone is the major metabolite formed in the 
metabolism of oxycodone and it was detected in only 5 of 10 sets of pre-burial 
hair samples (Day 18 to 30), with only one set at concentrations greater than the 
limit of quantification. 
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Table 20: Concentration of oxycodone and selected metabolites in rat hair (n =3) 
Analyte Oxycodone Noroxycodone Oxymorphone 
       Mean (±SD) (ng/mg) 
PBI (Days) Preburial Postburial Preburial Postburial Preburial Postburial 
0 2.18 (± 1.81) -- trace -- trace -- 
3 3.00 (± 1.39) 0.83 (± 0.76) ND ND ND ND 
6 3.00 (± 4.44) 1.07 (± 0.93) ND trace ND ND 
9 2.37 (± 0.64) 1.13 (± 0.99) ND ND ND ND 
12 1.73 (± 1.27) trace ND trace ND ND 
15 2.50 (± 0.44) ND ND ND ND ND 
18 2.40 (± 1.49) trace trace ND ND ND 
21 1.67 (± 0.64) ND 1.1 (± 0.56) trace ND ND 
24 0.97 (± 1.34) ND trace ND ND ND 
27 2.47 (± 3.06) ND trace ND ND ND 
30 trace trace trace ND ND ND 
Limit of Quantification= 0.78 ng/mg, Limit of Detection = 0.39 ng/mg; > LOD and < LOQ = trace; < LOD = ND. There is no “Postburial” 
analytical results for samples collected at Day 0, as those samples were not buried. Preburial = concentration of drug in hair samples 
collected from rats prior to burial in microcosms. Postburial = concentration of drug in hair samples collected from same rats after 
exhumation. 
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The concentration of oxycodone decreased or was not detectable in all hair 
samples after burial in soil (r2 = 0.14, p < 0.001). Oxycodone was not detected in 
any of the hair of control microcosms. This was expected, as the microcosms did 
not contain any rats or hair dosed with oxycodone.  
Soil collected from Day 3 exhumations did not contain any oxycodone or 
oxymorphone in two of the three replicates. This is reflective of the stage of 
decomposition of the rats as fresh rats were exhumed and minimal purging of 
bodily fluids from the carcasses was observed. From Day 6 to 24, and Day 30, 
collected soils contained oxycodone in at least 2 out of 3 microcosms. 
Oxymorphone was only detected in soil on Days 3, 12, and 15.  
 
4.3   Detection of Heroin Metabolites in Samples 
All liver samples collected from harvested carcasses were analysed for the 
presence of morphine and 6-MAM. However, morphine and 6-MAM were not 
detected in any of the liver samples of the rats studied in the second burial trial. 
This was not unexpected, as administration of heroin was discontinued 9 days 
prior to sacrifice and the elimination half-life of morphine and 6-MAM are 
approximately 2 - 3 hours and 6 - 25 minutes, respectively (Baselt, 2008). 
Because of the absence of heroin metabolites in liver, the heart tissue collected 
during this burial trial were not analysed for the presence of morphine or 6-MAM. 
Hair collected from the back of rats administered with heroin intravenously for 9 
consecutive days followed by nine days of abstinence prior to sacrifice, was 
collected prior to and after burial in a soil microcosm (Table 21). Preburial 
concentrations refer to the concentrations of morphine and 6-MAM in hair 
collected from the specific rats harvested prior to burial. The postburial 
concentration of morphine and 6-MAM refer to the concentration in hair collected 
from rats harvested on that specific day.  
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Morphine and/or 6-MAM were detected in hair samples collected prior to burial 
by UPLC-MS/MS by monitoring two transition ions utilising positive electrospray 
ionisation (Figure 19). There was no significant difference between the 
concentrations of 6-MAM and morphine observed before and after the burial 
intervals. However it should be noted that 6-MAM was only detected at trace 
levels after the first harvest interval of seven days and it was not detected in any 
samples collected from the harvested carcasses from day 14 to 56. Morphine 
was detected in four out of five sets of preburial samples; however analysis of 
samples collected from harvested carcasses from day 7 to 56 were all positive 
for morphine (Table 21). There was a large standard deviation of morphine and 
6-MAM. This may be due to the small sample set (n = 3) and high variability of 
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Figure 19: Extracted ion chromatograms of hair collected from a heroin-dosed rat, at 
postburial interval of 7 days, from 0 to 10 minutes.  
Transition ions for 6-MAM-D3: 330.97/165 and 330.97/211 at 3.36 minutes; 6-MAM: 
327.87/165 and 327.87/211 at 3.36 minutes; morphine-D3: 288.96/152 and 288.96/165 
at 2.55 minutes; and morphine: 285.92/152 and 285.92/166 at 2.55 minutes. 
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Table 21: Concentration of morphine and 6-monoacetylmorphine (6-MAM) in rat hair 
Post Burial 
Interval 
   Morphine    6-MAM 
Mean (±SD) (ng/mg) 
(Days) Preburial Postburial Preburial Postburial 
0 10.47 (± 18.13) -- 119.82 (± 206.27) -- 
7 0.91 (± 1.57) 19.47 (± 32.00) trace trace 
14 1.53 (± 2.66) 3.38 (± 5.23) 16.24 (± 23.67) ND 
28 ND 3.34 (± 5.78) 1.37 (± 1.37) ND 
42 1.53 (± 2.64) 24.31 (± 31.37) 16.61 (± 22.74) ND 
56 ND 1.37 (± 2.37) 3.14 (± 1.85) ND 
0 control ND -- ND  -- 
7 control ND ND ND ND 
14 control ND ND ND ND 
28 control ND ND ND ND 
42 control ND ND ND ND 
56 control ND ND ND ND 
Morphine Limit of Quantification (LOQ) = 0.08 ng/mg, Limit of Detection (LOD) = 0.04 ng/mg; 6-MAM LOQ = 0.31 ng/mg, LOD = 0.15 
ng/mg. > LOD and < LOQ = trace; < LOD = ND. There is no “Postburial” analytical results for samples collected at Day 0, as those 
samples were not buried. ND = not detected. Preburial = concentration of drug in hair samples collected from rats prior to burial in 
microcosms. Postburial = concentration of drug in hair samples collected from same rats after exhumation. 
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Morphine and 6-MAM were not detected in any of the grave soils. This is 
reflective of the absence of the drug analytes in collected liver samples. Drug and 
drug metabolites incorporated within the hair of the carcasses may have leached 
or diffused into the soil, however as the drug content was determined to be in the 
range of ng/mg of hair, the total drug content was minimal and below the limit of 
detection of this assay. Control rats were not administered heroin, thus the 










5.0   Discussion 
 A model to study taphonomic and toxicological changes in rats exposed to a 
burial environment was developed. The present study examined hair roots 
collected from oxycodone and heroin dosed rats, which were collected prior to 
and after burial for a specified period of interment in a burial microcosm. The 
effects of the decomposition process on the stability of the drugs incorporated 
into the hair roots were examined. Although previous studies have examined the 
effects of decomposition on the morphological structure of hair (Pötsch et al., 
1995; Tebbet, 1999; Wilson et al., 2001; Wilson et al., 2007)); the rate of drug 
incorporation into the hair shaft (Gygi, Wilkins, & Rollings, 1995; Gygi, Joseph, 
Cone, Wilkins, & Rollings, 1996; Rothe et al., 1997; Toyo’oka et al., 2001); the 
stability of the drugs in collected hair samples of known addicts (Gaillard & Pépin, 
1998; Girod & Straub, 2001); or the stability of drugs in hair samples collected 
from mummified subjects (Cartmell et al., 1991), no other published studies have 
examined the effect of an actively decomposing body on the stability of 
incorporated drugs in hair.  
 
5.1  Method Selection and Optimisation 
To examine the drug content of hair samples, protocols on the collection, 
preparation, extraction, and analysis of samples were developed. The collected 
hair samples underwent a decontamination process prior to analysis to minimize 
any potential external bias. Samples were rinsed in a non-polar halogenated 
solvent, which were subsequently analysed for the presence of drugs. Methanol 
was chosen as the extraction solvent for hair as all the analytes of interest were 
soluble in methanol and was also amiable to sample reconstitution for analysis 
on the UPLC-MS/MS. Use of methanol as the choice of extraction solvent was 
supported by Stout, Ropero-Miller, Baylor, and Mitchell (2007). Their study 
demonstrated that methanol was capable of lifting the scales of the hair shaft and 
solubilising the cell membrane complex without damaging the structure. 
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Methanol also causes the hair shaft to swell, which enables the solvent to 
remove more lipid from hair than non-swelling solvents like dichloromethane 
(Robbins, 2002). Thus using dichloromethane as a decontamination rinse prior to 
a methanol extraction should have only removed external contaminants from the 
hair shaft. To ensure that the rinse solutions did not penetrate the hair shaft, the 
rinse solution was analysed for the presence of oxycodone or heroin metabolites.  
When selecting hair for drug analysis, the site of hair collection was taken into 
consideration. The back or dorsal surface of the rat was chosen as the site of 
sample collection, despite the large surface area available. The hair on the 
abdomen, lower surface and extremities was avoided as the potential for external 
contamination was greater, i.e. such surfaces would have a greater likelihood of 
coming into contact with urine, fecal material, and saliva, which may have 
contained drug and drug metabolites. The pattern of decomposition may have an 
impact upon the microenvironment upon which the sampled hair was exposed to. 
For example, hair collected from the perianal region would be more susceptible 
to ante- and postmortem contaminants as the anus, an existing orifice, would be 
a route for fluid expulsion during active decomposition (Pinheiro, 2006). Another 
consideration is that decomposition may vary within the carcass itself, as was 
observed in the burial trials; one portion of the body was desiccated while 
another portion remained moist and putrefied (see Figure 12).  
 
5.2  Experimental Approach 
Postmortem redistribution (PMR) is a term used to describe the drug 
concentrations in samples collected postmortem, which may not accurately 
reflect antemortem drug levels as the concentrations of various drugs may 
increase or decrease after death. Many studies regarding the postmortem 
redistribution and stability of drugs have utilised human subjects obtained from 
autopsies conducted through medical examiner’s or coroners’ offices (Stevens, 
1984; Pounder, Hartley, & Watmough, 1994; Moriya & Hashimoto, 1997; Hadidi 
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& Oliver, 1998; Moriya & Hashimoto, 1999). The use of animal models including 
the pig, rabbit and rat has also shown reasonable agreement with human cases 
when studying PMR (Hilberg et al., 1992; Pounder et al., 1994; Hedouin et al., 
1999; Hilberg, Rogde, &  Mørland, 1999; Moriya & Hashimoto, 1999), thus rats 
were utilised for this study. Another reason for using a human analogue was due 
to the ethical issues and availability of drug positive human hair and decomposed 
remains. The use of rats as human analogues has been well established in 
forensically relevant pharmacological as well as taphonomic studies (Tomberlin & 
Adler, 1998; Aturaliya & Lukasewycz, 1999; Hilberg et al., 1999; Casamatta & 
Verb, 2000; Carter et al., 2007). Sprague-Dawley rats administered oxycodone or 
heroin were used to study the stability of drugs incorporated in hair postmortem 
and controlled laboratory experiments. The use of the rats also helped to control 
the dose, route of drug administration, drug use history and manner of death, 
which are forensically relevant factors. The collection of hair from rats prior to 
burial in the soil microcosms allowed for direct comparison of how the 
decomposition process would alter the drug content in each individual rat, as hair 
was collected from the same specimen and tested for its drug content.  
The burial microcosms utilised in this study attempted to control variables such 
as grave depth, soil type (including initial soil pH and moisture level), air 
exchange, and temperature. The control rats in the second trial demonstrated 
that the rate of decomposition was unaffected by previous drug exposure as 
visual observations were similar between the heroin-treated rats and the control 
rats. The heroin-administered rats had no heroin injected for a period of nine 
days prior to sacrifice, thus the drug and drug metabolites were cleared from the 
body’s blood and urine (Baselt, 2008) as it was unknown if the presence of 
heroin may have had an effect on the activity of the bacterial microorganisms 
which utilised the body as a nutrient source.  
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5.3  Progression of Decomposition 
For both burial trials, as the burial interval increased, the carcasses progressed 
through the Fresh, Inflated/Bloated, and Active stages of decomposition. In the 
second trial the carcasses progressed to Advanced Decay. The pH of the soil 
and tissue fluctuated as the rats decomposed; the soil pH was initially measured 
at 6.8 and decreased to 5.0 at day 27, where as the liver pH was initially 
measured at 6.1 and increased to 8.5 by the end of the burial trial at day 30 (see 
Figure 13). The changes in relative pH may be due to the activity of the autolytic 
enzymes present within the body and the formation of putrefactive amines. The 
total mass of the carcasses also decreased over time (see Appendix A and B) 
while the soil moisture increased, however the total mass of the burial microcosm 
did not change over time, and the loss in mass of the carcasses may be 
attributed to purging of bodily fluids and moisture into the soil.  
The first burial trial with oxycodone had a harvest interval of 3 days, for a total 
decomposition period of 30 days. The rats in this trial did not progress beyond 
the active stage of decomposition. In an attempt to capture the later stages of 
decomposition (Advanced and Skeletonisation/Dried Remains) in addition to the 
early stages thereby examining the entire decomposition process, the harvest 
interval was increased to 7 then 14 days, for a total harvest interval of 56 days. 
The rats in the second trial did not progress beyond the initial portion of 
Advanced decomposition, which may last for months before progressing to dried 
remains (Rodriguez, 1997; Pinheiro, 2006; Ferner, 2008). It was expected that by 
extending the total burial interval, the pH of the soil may return to basal levels. 
The pH of soil in the second burial trial was initially measured at 6.2 and 
decreased to 5.0 by day 14 and returned to basal levels by day 56. However the 
liver pH did not return to basal levels as the soil pH did; instead the liver pH 
continued to increase from an initial 6.0 to 8.0 by day 56. It was hoped that soil 
pH could be linked to tissue pH and drug stability, however more work is 
required. Research conducted in 1995 and 1996 (Pötsch et al., 1995; Pötsch & 
Skopp,1996) examined the stability of incorporated drugs in hair upon exposure 
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to cosmetic treatments, including perming, bleaching, and colouration of hair, and 
incubation in soil and water. However the hair samples were all collected from 
known users (i.e. clipped from the scalp) before being subjected to various 
treatments. Although hair is essentially inert, it has the ability to incorporate drugs 
and various compounds through passive contamination and diffusion from the 
intact root after death (Kintz, 2004). The cosmetic treatments would have 
exposed hair specimens to different pH environments, including a basic solution 
for perming and an acidic solution for bleaching, both of which resulted in 
decreases of drug content. Soft tissue decomposition exposes the hair shaft to a 
unique mixture of chemical compounds not observed in just soil or water, i.e. 
blood and putrefactive gases/liquids. Although Pötsch et al. (1995) demonstrated 
that exposure of opiate positive hair to soil for a period of six months decreased 
the drug content, the rate of drug instability and etiology for the decrease in drug 
content were not identified. This research measured the drug content in hair, 
which was freshly plucked from decomposing carcasses buried in soil. The 
oxycodone concentrations decreased in hair as the burial interval increased in 
soil and this may be due to diffusion of drugs out of the hair shaft as it was 
exposed to the moisture of the soil and putrefactive fluids of the body.  
The increase in liver pH observed in both burial trials may be due to cell autolysis 
and the putrefactive processes related to decomposition. Microorganisms 
present in the intestinal organs can multiply and spread to breakdown connective 
tissue to release cellular components, including pH sensitive autolytic enzymes. 
The decomposition of nitrogen containing proteins to form amines can lead to the 
increase of pH in tissue, as was observed in liver samples (Stevens, 1984; Gill-
King, 1997; Skopp, 2004). 
The organic matter released by decaying carcasses, including putrefactive gases 
and liquids such as methane, hydrogen sulphide and lactic acid, are incorporated 
into soil, to form a decomposition island, which is rich in nitrogen, carbon and 
phosphorus. The decomposition of carbohydrates from the decaying body in soil 
may have resulted in the observed initial decrease in soil pH.  
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5.4  Effect of Decomposition on Soft Tissue 
The pH of liver samples increased from approximately 6.0 to over 8.0 as the 
decomposition trial progressed. Under physiological conditions, plasma pH is 
approximately 7.4 and cellular pH is approximately 5.0 (Ferner, 2008). Weak 
bases in their nonionized state in the plasma can permeate through cell 
membranes due to the pH gradient to accumulate in tissues. With the increase in 
pH, the weak bases, including oxycodone, may diffuse back out of the tissue and 
into the extracellular fluid of the body. As the liver pH increased, the oxycodone 
in the liver may have diffused out of the tissue and into neighbouring organs and 
the vascular compartments. With purging of bodily fluids from the carcass, the 
oxycodone would have diffused out of the body and into the surrounding 
environment, namely the soil. Oxycodone was detected in the majority of soil 
samples from day 6 and onwards, which would be consistent with visual 
observations of the carcasses undergoing bloating and purging from the inflated 
and active stages of decomposition.  
In the second burial trial, both the liver and heart were collected from each 
carcass. Because of the negative drug findings of the liver samples, the collected 
heart samples were not analysed for the presence of morphine or 6-MAM.  The 
samples were analysed for their pH, however the pH of the heart homogenates 
and liver homogenates were not significantly different (see Appendix B) from 
each other. Upon dissection, the diaphragm was found to be intact in most of the 
carcasses exhumed; at days 42 and 56 the structures of the diaphragms were 
compromised (see Figure 15, Day 42 and 56). The intact diaphragm can act as a 
physical barrier, to shield the heart and lungs from the putrefactive liquids and 
gases formed from the intestinal organs. When the carcasses progressed from 
the inflated stage to deflated/active decay stage, the heart remained largely 
protected, thus it was expected that there would be a difference between the pH 
of the heart and liver as the liver would have been exposed to a greater variety of 
putrefactive enzymes from its proximity to the digestive system and the enzyme 
load of the liver itself. That there was no significant difference between the pH of 
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the heart and liver was unexpected; however this may be due to the fact that the 
vascular system was relatively intact and it was exposed to the same burial 
environment.    
 
5.5  Oxycodone in Liver 
The burial microcosms were maintained at room temperature (20-22 degrees 
Celsius) and the livers of oxycodone-dosed rats were collected upon exhumation. 
The concentrations of oxycodone in liver could not be established in each 
carcass prior to burial in the soil microcosms as this would have required 
harvesting part of the organs. The analytical extraction chosen for liver sample 
analysis was protein precipitation by acetonitrile. Concentrations of oxycodone 
and its metabolites decreased as the post-burial interval increased. Oxycodone 
was not detected in the last set of replicates exhumed at Day 30, while 
noroxycodone and oxymorphone were not detected from days 12 and 18, 
respectively. This decrease in drug content may be due to postmortem 
degradation and/or metabolism by bacteria and other microorganisms present 
during the putrefactive process. Moriya and Hashimoto (1997) demonstrated with 
in vitro experiments that conjugated morphine converted to free morphine in liver 
samples at 18 - 22 and 37 degrees Celsius during a ten-day period, resulting in 
an apparent rise in free morphine concentration over time. Robertson and 
Drummer (1998) reported that nitrobenzodiazepines, including clonazepam, 
nitrazepam and flunitrazepam, are metabolised to their respective 7-amino 
metabolites in various tissues by enterobacteria containing oxygen-sensitive 
nitroreductase enzymes. These results are in good agreement with previously 
published studies regarding the stability of drugs in postmortem samples, as 
longer postmortem intervals can lead to unexpected findings following the 
analysis of liver (Stevens, 1984; Pounder & Davies, 1994; Pounder et al., 1994; 
Moriya & Hashimoto, 1997). 
 
 96 
5.6  Oxycodone in Hair 
Studies published by Gygi et al. (1995, 1996) have determined the distribution of 
codeine and morphine into rat hair after long-term daily dosing over a time 
course of 21 days, as well as plasma and hair concentrations of codeine and its 
metabolites in male Sprague-Dawley rats over a five-day dosing regime. 
Toyo’oka, Tano, Kato, and Nakahara (2001) established that a single 
intraperitoneal administration of morphine hydrochloride can be detected in hair 
shafts and roots of Dark Agouti rats. In this study, Sprague-Dawley rats were 
administered oxycodone or heroin over a five or nine-day period, respectively. 
The oxycodone-administered rats were sacrificed on their last day of treatment; 
however the heroin-administered rats were not administered any drug for a 
period of nine days prior to sacrifice. Both treatment periods were sufficient to 
incorporate the administered drug or drug metabolite into the hair shaft of the rat 
at a level that could be detected by the current method of analysis. 
Oxycodone was detected in hair root samples of rats administered oxycodone for 
a period of five days intravenously prior to sacrifice; however its metabolites, 
noroxycodone and oxymorphone were not detected at quantifiable levels. The 
concentrations of oxycodone decreased in all samples regardless of the 
interment period (range: 3 – 30 days). In selected samples (Day 15 and 
onwards), oxycodone was no longer detected in quantifiable levels in hair after 
exhumation. Although there have been other studies regarding the analysis of 
postmortem hair samples for the presence of oxycodone (Deveaux & Pépin, 
2006; Moore, Marinettii, Coulter, & Crompton, 2008), there have been no 
published reports regarding the stability of oxycodone in hair collected from 
decomposing bodies. Factors which may have contributed to the decrease in 
drug concentration include the presence of soil microbes, increased moisture 
content of the soil and changes to soil pH, and exposure of the hair roots to 
putrefactive liquids produced by the carcass as decomposition progressed. 
Water is a fundamental component of hair and the moisture content of hair alters 
in relation to the relative humidity of the environment (Downes, 1961). The 
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amount of moisture in hair can affect its physical properties. The peptide bonds 
and hydrophilic side chains of keratin fibers contribute to water sorption; at 
humidity below 25%, water is principally bound to hydrophilic sites of the fibre by 
hydrogen bonds. As the humidity increases, additional water is sorbed and as the 
humidity increases above 80%, multimolecular sorption (water binding to water) 
is evident (Robbins, 2002). As hair is exposed to liquid, the cuticles and hair shaft 
swell and open up. This creates a possible opportunity in which drugs present in 
the hair shaft may leach out to effectively decrease the concentration upon 
exhumation and analysis. The drug bound to hair may either be displaced by the 
water or diffuse out of the hair shaft as a result of a concentration gradient.  
The unidentified white fungal growth on the carcasses observed from day 3 and 
onwards may have also contributed to the decrease in drug content (see Figure 
10, Figure 17). Soil and intestinal microorganisms in addition to fungal growth 
and activity can alter the structure of hair (Wilson et al., 2007), thus altering any 
compounds which may be incorporated within the hair shaft. Fungal tunnelling of 
the hair shaft would have compromised the physical structure of the hair shaft 
allowing for greater access of soil microbes to utilize the hair as a nutrient 
source. Subsequently the drug content of the hair would be expected to decrease 
in relation to the structural integrity of the hair. The hair collected from exhumed 
cadavers was not examined at a microscopic level, however they were noticeably 
less pliable and rigid compared to samples collected prior to burial. The rigidity 
may be due to exposure to the fungal growth or decomposition fluids. 
 
5.7  Heroin Metabolites in Hair 
Heroin is quickly deacetylated to 6-monoacetylmorphine (6-MAM) and morphine 
in the body and the presence of 6-MAM in biological fluids and hair is required to 
distinguish between heroin and morphine administration (Society of Hair Testing, 
2004). Because of the short half-life of heroin and its metabolites in blood and 
urine, hair is a better matrix to analyse when attempting to establish a history of 
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drug use or abuse, i.e. previous administration of heroin, as drug and drug 
metabolites can be detected in hair long after drug exposure (Polettini, Stramesi, 
Vignali, & Montagna, 1997; Girod & Staub, 2001; Darke et al., 2002; Jones, 
Tomlinson, & Moore, 2002; Druid et al.,  2007; Kronstrand et al., 2007). The 
major metabolites of heroin, namely morphine and 6-MAM, have been positively 
identified in hair of known addicts (Girod & Staub, 2001). 6-MAM and morphine in 
the majority of samples, were identified in hair samples collected from preburial 
heroin-administered rats, thus confirming that the rats were administered heroin 
and not morphine, which is in good agreement with other published studies 
regarding the presence of 6-MAM in hair of known heroin users (Kronstrand, 
Grundin, & Jonsson, 1998) or in animal models administered heroin (Nakahara, 
Takahashi, Shimamine, & Saitoh, 1992; Nakahara, Kikura, & Takahashi, 1994; 
Gaillard & Pépin, 1998; Girod & Staub, 2001).  
After nine consecutive days of heroin treatment, the rats in this study underwent 
a nine-day period of abstinence, thus with the short half-life of heroin and its 
metabolites, any trace of their drug use history would not be evident in tissue or 
fluid (blood or urine) analysis. In this study, all liver samples analysed for the 
presence of 6-MAM and morphine were negative, thus if trying to establish a 
drug history of these rats, liver analysis would not have been informative. 
Analysis of preburial hair samples on the other hand, provided evidence of past 
heroin administration, which may be helpful in a forensic investigation. However, 
the 6-MAM detected in preburial samples (trace levels in one set of samples) 
was not detected at quantifiable levels in samples collected from the same rats 
after burial. The degradation of 6-MAM is most likely due to non-specific 
hydrolysis upon exposure to the moist environment created by the decomposition 
process and autolytic enzymes present in the body.  
Morphine was detected in hair samples collected from rats, which were exhumed 
on days 7, 14 and 42. The corresponding postburial samples collected were still 
positive for morphine. An interesting finding was that there were two sets of 
preburial samples in which morphine was absent or present at levels below the 
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limit of detection or quantification (Day 28 and 56), however the corresponding 
postburial samples were positive for morphine. This may be attributed to the 
decomposition of morphine’s parent compounds, either heroin or 6-MAM and/or 
sample variability. It was observed that 6-MAM was not stable during the burial 
process, and as morphine is a product of 6-MAM hydrolysis, it is possible that the 
morphine was produced postmortem during the decomposition process.  As part 
of the validation procedure, a QC sample containing only 6-MAM was analysed 
to demonstrate the stability of 6-MAM during the extraction and analysis process, 
thus any degradation attributed to 6-MAM in the samples was not due to the 
analytical method. 
As putrefaction and decomposition progress with the postburial interval, the 
determination of 6-MAM’s presence becomes more difficult. The ability to 
distinguish between heroin and morphine administration cannot be made if  
6-MAM is not detected, thus when analysing samples from an exhumed 
individual, it may not be possible to confirm heroin use as part of their drug 
history through hair analysis. Because morphine was still detectable in samples 
after 56 days, the exposure to an opioid cannot be excluded.  
 
5.8  Limitations 
The hair of the rats was in different stages of growth and therefore the drug 
uptake would have been variable between individual strands. To account for this, 
in future research, the area of sample collection could be shaved. The rats would 
then be dosed with the drug and as the hair grew back it would be taken up by all 
of the hair at the same rate. This recommendation would eliminate this variable in 
the present research, which at this point cannot be accounted for.  
Another confounding factor is that the dose of any particular drug has not been 
correlated to concentrations found in hair. The pharmacokinetics of drugs in hair 
has not been established or studied as extensively as the disposition of drugs in 
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blood and urine. Thus concentrations of oxycodone and heroin metabolites found 
in hair may not correspond to the dose administered, which may also account for 
the large variability in hair samples analysed for morphine and 6-MAM.  
This study only examined the disposition of two opiates, oxycodone and heroin, 
in non-pigmented rat hair. Drugs with different chemical characteristics may have 
greater stability than the two examined. For example, drugs with greater 
lipophilicity may be more stable in hair as the hair shaft would act as a lipophilic 
reservoir, which would be resistant to hydrolytic actions of the decomposition 
process. Other drug characteristics which may affect stability include pKa and 
molecular size, as a drug with a simple small chemical structure may diffuse 
through cellular membranes more freely than a larger complex structure.  .  
The hair samples examined in this study were derived from Sprague-Dawley 
rats, which have nonpigmented (white) hair. As the drugs that were administered 
are weak bases (i.e. oxycodone) and amphoteric (i.e. morphine derived from 
heroin), it can be expected that pigmentation of hair would have an effect on the 
initial concentrations of drug as one study found that black hair incorporated 
codeine (a weak basic drug) up to 44-times greater than nonpigmented hair in 
rats (Gygi et al., 1996). The effect of decomposition on the stability of drugs may 
or may not change, as the exact mechanism and components of drug 
incorporation into hair has not been clearly elucidated. Thus it may be of interest 
to repeat the burial trials in pigmented hair, as it could lead to different results. 
Ideally, if the studies could be replicated in rats which contained both 
nonpigmented and pigmented hair, drug uptake and stability could be examined 
within the same animal. The stability of oxycodone and heroin metabolites may 
be greater, as melanin may be an important drug binding site (Hubbard, Wilkins 
& Rollins, 2000). If melanin is more resistant to degradation in a burial 
environment and it also serves as a significant binding site for drugs, it can be 
expected that there would be greater drug stability in such samples.  
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The first burial trial lasted 30 days, while the second burial trial was extended to 
56 days. However with both trials, the rats did not progress beyond active 
decomposition. If the remains were allowed to progress to skeletonisation, where 
no tissue would be available for analysis, the results of hair testing may be more 
important as it would be the only specimen remaining other than bone. 
Oxycodone was not detected in samples exhumed at the later portion of the 
decomposition trial in levels above the limit of quantification after only 12 days. 
Morphine was detected in hair after 56 days, however because of the limited 
number of rats and the destructive nature of the harvest, it was not determined if 
morphine would be detected in hair samples from skeletonised remains. 
 
5.9  Future Work   
Factors such as body positioning, grave depth, absence/presence of clothing, 
and desiccation rate were not examined and were beyond the scope of this 
study; it is recognized that such factors may influence the rate of decomposition 
(Aturaliya & Lukasewycz, 1999). For example, an outdoor surface burial would 
have exposed the carcasses to insects and scavengers, resulting in an 
accelerated rate of decomposition which may have produced limited sample 
availability (Carter et al., 2007).  
Further work should be explored to determine how the burial environment and/or 
the general process of decomposition altered the concentrations of drugs 
incorporated into hair. An outdoor burial trial would expose carcasses to an 
environment which would have fluctuating temperatures and moisture, as well as 
potential scavenging by insects and animals. The rate of decomposition should 
not be very different from the rate of decomposition observed with the indoor 
burial trials during the summer months; however in Southern Ontario, the winter 
season would result in exposing the carcasses to sub-zero ground temperatures, 
essentially halting the decomposition process.  
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Surface trials could be undertaken to determine the effects on drug stability. As 
the decomposition process would be expected to occur at an accelerated rate, 
compared to burial trials, the oxycodone and/or heroin metabolites may have 
decreased in concentration at a faster rate. Outdoor surface decomposition trials 
also have other variables to consider, including temperature fluctuations, 
moisture and humidity changes, scavenging and insect activity, as well as UV 
exposure from sunlight. Exterior environments expose the body to weathering. 
Weathering effects in human hair have been studied by comparing tip ends to 
root ends. Robbins (2002) examined the effects of ultraviolet light on hair and 
hair from root and tip sections to examine sulphur in hair. The data suggests that 
cystine and tryptophan in hair is sensitive to photochemical degradation 
(Robbins, 2002). As weathering can alter the basic structure of hair, it can be 
expected that any drugs incorporated within the hair structure would also be 
compromised, as demonstrated by Skopp et al. (2000). Their study collected 
cannabinoid positive hair and exposed them to various storage conditions; 
eleven different samples exposed to natural sunlight for ten weeks all decreased 
in cannabinoid content. 
To study the effect of surface decomposition in an exterior environment, drug 
administered rats could be placed on a soil surface in an outdoor field 
environment and allowed to decompose. Hair could be collected from the 
decomposing carcasses at various stages of decomposition, while monitoring soil 
moisture, soil pH, precipitation, temperature, and UV radiation.  
The fungal growth observed during both burial trials may have influenced the 
stability of drugs in hair, as fungal tunnelling can alter the basic structure of the 
hair shaft. Attempts to characterise the white growth should be undertaken in 
future work as it may play a role in hair integrity and drug stability. In future burial 
microcosms, any fungal samples should be collected and characterised. Drug 
positive hair could be inoculated with either soil or fungal samples to determine 
its effect on hair integrity and drug stability.  
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Because of the short dosing regime of the rats for both burial trials (five to nine 
days of drug exposure), segmental hair analysis was not performed. If the rats 
had been acutely and/or chronically exposed to a drug or mixture of drugs over a 
longer time period, segmental hair analysis could have been undertaken and the 
stability of drugs incorporated in the mid to distal ends of the hair shaft could be 
examined. The hair roots examined in this study were in closer proximity to the 
epidermis than the soil, thus the rate of drug stability may differ between different 
regions of the hair shaft.  
Although hair is a matrix, which is generally considered to be a convenient 
sample of analysis because it is less intrusive and more readily available than 
urine or blood, utilising hair in postmortem toxicology analysis may have more 








6.0   Conclusion 
Methods for the detection and quantification of oxycodone, noroxycodone, 
oxymorphone, 6-monoaceytylmorphine and morphine using LC-MS/MS in soil, 
liver, and hair were developed and validated. One MRM transition was selected 
for the analysis of oxycodone and its metabolites. However with the second 
burial trial and set of method development, two MRM transitions were selected 
for the analysis of heroin metabolites for improved selectivity.  
The oxycodone concentrations within the liver of treated rats decreased as the 
post mortem/burial interval increased. Over a 30-day period, the concentrations 
were assessed and oxycodone was not detected after 30 days. Heroin 
metabolites were not detected in any of the liver samples, thus the stability of 
morphine and 6-MAM in liver samples could not be examined. 
The concentrations of oxycodone and heroin metabolites were assessed in hair. 
Hair samples collected before burial were compared to hair samples collected 
upon exhumation from burial microcosms. The concentrations of oxycodone 
decreased as the interment period increased and were not detected at levels 
above the limit of quantification after day 12. The concentration of 6-MAM was 
detected in preburial samples but not detected in postburial samples, whereas 
concentrations of morphine fluctuated and was detected in some previously 
negative samples and for as long as 56 days postburial, however the differences 
were not significant.  
Heroin metabolites and oxycodone can be detected in hair even after dosing 
periods as short as five to nine days. Testing for the presence of drugs in hair 
can be more informative than testing in liver as the window of drug detection is 
greater in duration in hair than in liver as was the case for the heroin-
administered rats. Hair analysis has the potential to be used to help establish a 
partial drug history of the decedent, which may also help in the identification of 
unknown remains. However as decomposition progresses, the absence of 
certain analytes should not be interpreted as abstinence of drug use as this study 
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has shown that 6-MAM and oxycodone within hair are not stable in burial 
environments. Within each set of hair samples, variations in drug concentrations 
were observed and the different drugs showed different degrees of stability in 
hair; 6-MAM was detected at only trace amounts after just seven days of burial; 
oxycodone was still detected in samples after two weeks of burial; whereas 
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8.0  Appendix A Trial 1 Oxycodone Rat Data 
Trial 1: February 2008 to March 2008, n = 30 
 







Mass of Liver 
(grams) 
0 427.38  N/A 13.69 
3 472.59 (37.38) 5.88 (3.26) 9.39 (0.79) 
6 438.43 (10.50) 5.96 (8.85) 8.64(1.85) 
9 356.53 (22.27) -3.82 (1.80) 4.74 (0.60) 
12 379.50 (8.06) -9.09 (4.21) 4.77 (1.72) 
15 364.6 (14.48) -11.33 (3.22) 5.42 (1.09) 
18 367.79 (31.52) -11.42 (4.25) 6.09 (2.23) 
21 329.24 (13.07) -14.72 (0.93) 4.91 (0.34) 
24 385.35 (49.30) -21.71 (4.82) 6.33 (1.67) 
27 297.42 (11.71) -20.58 (2.06) 5.23 (1.75) 
30 313.67 (9.84) -21.20 (3.76) 4.88 (0.29) 
n = 3, Mean (± SD) 
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Soil Moisture (%) Soil pH Liver pH 
0 50.0 6.8 6.30 
3 50.0 6.8 (0) 6.30 (0.20) 
6 50.0 6.7 (0.1) 6.50 (0.20) 
9 55.0 6.0 (0) 7.25 (0.10) 
12 60.0 6.0 (0) 7.23 (0.67) 
15 55.0 6.0 (0.1) 7.30 (0.20) 
18 60.0 5.6 (0.2) 7.40 (0.20) 
21 60.0 5.4 (0.2) 7.90 (0.20) 
24 60.0 5.5 (0.1) 7.63 (0.60) 
27 60.0 5.2 (0.2) 8.20 (0.20) 
30 60.0 5.7 (0.2) 8.30 (0.20) 
n = 3, Mean (± SD) Initial soil moisture and pH for all microcosms were standardized to 50% 
moisture and pH of 6.8. 
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8.1  Appendix B Trial 2 Heroin Rat Data  
Trial 2: February 2009 to March 2009  
Heroin Dosed Rats, n = 18; Control Rats, n = 6 
 















0 515.39 (±36.21) N/A 18.53 (±0.79) 1.84 (±0.74) 
7 514.86 (±45.12) -0.75 (±0.93) 11.59 (±0.24) 1.96 (±0.21) 
14 521.89 (±39.37) -11.35 (±1.11) 7.81 (±0.43) 1.50 (±0.20) 
28 538.84 (±49.63) -14.04 (±1.47) 7.06 (±1.60) 1.59 (±0.13) 
42 538.40 (±33.67) -24.97 (±5.40) 5.81 (±1.04) 0.95 (±0.13) 
56 539.14 (±30.48) -35.68 (±1.50) 7.62 (±1.74) 1.38 (±0.45) 
Control     
0 462.29 N/A 17.78 2.09 
7 531.00 -0.44 14.94 1.69 
14 510.34 -14.91 10.15 2.20 
28 437.42 -19.73 5.54 1.57 
42 509.21 -17.93 7.13 0.67 
56 449.74 -35.61 6.06 0.78 
At each harvest: Control, n = 1. Heroin treated rats, n = 3.  Mean (± S.D.) 
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Soil pH Liver pH Heart pH 
Heroin      
0 60.0 6.2 6.04 (±0.30) 6.17 (±0.29) 
7 65.0 (±0) 5.3 (±0.1) 5.98 (±0.16) 7.00 (±0.50) 
14 73.3 (±2.9) 5.1 (±0.1) 6.63 (±0.18) 7.00 (±0.0) 
28 80.0 (±0) 5.6 (±0.0) 7.71 (±0.51) 7.83 (±0.29) 
42 95.0 (±0) 5.9 (±0.1) 7.86 (±0.16) 7.67 (±0.29) 
56 90.0 (±0) 6.1 (±0.1) 7.87 (±0.19) 8.00 (±0.0) 
Control     
0 60.0 6.2 6.18 7.00 
7 60.0 5.5 6.08 7.50 
14 65.0 5.2 6.63 8.00 
28 70.0 5.4 8.14 8.50 
42 90.0 6.0 7.93 8.00 
56 90.0 6.0 7.96 8.00 
At each harvest: Control, n = 1. Heroin treated rats, n = 3.  Mean (± SD) 
 
